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Why study nerve growth factor in relationship to asthma?
In November 1996 a review article appeared carrying the title "Nerve growth
factor: from neurotrophin to neurokine" (1). The review described a new role for
nerve growth factor (NGF) in inflammatory responses. Hence, the classification of
NGF as neurotrophin, a protein that induces outgrowth of neurons, was suggested
to be changed into neurokine, indicating a similarity to cytokines and thus a role in
immunological responses. This publication by Nobel Prize winner Rita Levi-
Montalcini and colleagues was in view with our ideas on the possible role of NGF
in allergic asthma. This introduction elaborates on the possible role of NGF in
allergic asthma.
Allergic asthma
A reversible airway obstruction, airway inflammation and an increased sensitivity
to bronchoconstrictive stimuli characterize allergic asthma, the latter phenomenon
is also referred to as airway hyperresponsiveness (2-4). Two distinct phases can be
discriminated: an early and a late asthmatic response. The early phase involves
acute bronchoconstriction, extensive vascular leakage and mucus hypersecretion,
immediately after allergen challenge; this usually resolves within 1-2 hrs. The early
asthmatic response is mainly caused by products released from mast cells, as
allergen specific IgE, induced during a preceding sensitization period, induces
massive mast cell activation at the time of allergen challenge (5). One of the
important mediators, released by mast cells and responsible for early phase effects
is histamine (6). The early phase can be followed by a late phase several hours
after the allergen challenge. Infiltration of inflammatory cells in the airways,
epithelial shedding, mucus hypersecretion and bronchoconstriction characterize
this phase (7, 8). The late response and airway hyperresponsiveness are associated
with increases in airway eosinophils and release of inflammatory mediators and
cytokines (4, 7, 9-11). The mechanism by which the allergic response relates to
airway hyperresponsiveness and respiratory smooth muscle reactivity is still a
matter of debate (recently discussed in 12).
Neurogenic inflammation
Neurogenic inflammation contributes to pathological phenomena in several
diseases. For example, in asthma (13), in inflamed skin (14) and in neuropathic
pain (15). Neurogenic inflammation involves a change in function of sensory
neurons due to inflammatory mediators, thereby inducing an enhanced release of
peptides from the nerves (13). Sensory neurons are characterized by their
expression of certain peptides, the tachykinins. The pungent derived from red
peppers, capsaicin, induces release of tachykinins. Sensory neurons are sensitive to
capsaicin, indicating that these neurons are expressing the vanilloid receptor 1
(VR1; 16, 17). Sensory nerves containing tachykinins are also referred to as
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excitatory non-adrenergic, non-cholinergic (eNANC) nerves. This as opposed to
inhibitory NANC (iNANC) nerves, containing vasoactive intestinal peptide and
nitric oxide (48).
Several studies have shown a role for neurogenic inflammation in the induction of
airway hyperresponsiveness in animal models, in particular for the tachykinins
substance P and neurokinin A. Examples are: 13-hydroxyoctadecadienoic acid-
(20), IL-5- (21), ozone- (22), citric acid- (23), and toluene diisocyanate-induced
(24) airway hyperresponsiveness. Guinea pigs sensitized to and challenged with
ovalbumin, as a model for allergic asthma, show an increase in substance P
immunoreactive neurons in nodose ganglia (25, 26). Tachykinin levels are elevated
in plasma during the exacerbations of asthma and in lavage fluids after allergen
challenge (27, 28). Moreover, protective effects on the induction of allergic airway
pathology by neurokinin receptor antagonists have been reported (29).
NGF is able to augment neurogenic inflammation (30) and perhaps in this way
plays a role in allergic asthma. NGF specifically upregulates synthesis of products
of the preprotachykinin gene, which codes for several tachykinins, such as
substance P and neurokinin A (31-36). Moreover, NGF changes the properties of
sensory nerve endings by inducing a very fast accumulation of second messengers
(37) or phosphorylation of key transduction-related proteins or ion channels,
thereby sensitizing the peripheral sensory nerve ending (37, 38). Similarly, over-
expression of NGF specifically in the airways of mice leads to an enhanced
sensory and sympathetic innervation of the airways. These mice were more
sensitive to capsaicin, which induced increases in airway resistance (39).
The protein NGF and its receptors
NGF belongs to the family of neurotrophins, which control the survival,
differentiation and maintenance of neurons in the peripheral and central nervous
systems (40). NGF is a homodimeric molecule (41). Two molecular forms of NGF
exist: 7S NGF and 2.5S NGF molecules (42, 43).
Nerve growth factor can interact with two receptors: either the tyrosine kinase
receptor A (trkA) or p75. TrkA is a receptor with tyrosine kinase activity that
forms a high-affinity binding site for NGF (Kd ≈ 10-11M, 44). NGF binds to the
trkA receptor and the NGF-trkA complex is internalized and retrogradely
transported to the nucleus, where mRNA levels for preprotachykinin, the precursor
for tachykinins, are affected (34, 35). Alternatively, trkA activation leads, in a
tyrosine kinase-dependent manner, to phosphorylation of proteins at the nerve
terminal, which can induce changes in the properties of the nerve ending (37, 38).
The receptor p75 can bind several neurotrophic factors with nanomolar affinity:
NGF, brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and NT-4
(reviewed in 61). The p75 low affinity NGF receptor also causes an upregulation in
tachykinin content in sensory nerves (45).
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NGF and inflammation
Several inflammatory mediators, including interleukin-1, interleukin-4, interleukin-
5, tumor necrosis factor α and interferon-γ, induce release of NGF (46, 47). In
addition to neurons, also non-neuronal cells such as mast cells (48), fibroblasts
(46), T-cells (49, 50), B-cells (51), eosinophils (52) lymphocytes (51) and airway


















Besides neurons, different types of inflammatory cells, such as macrophages, mast cells,
eosinophils, B-cells and T-cells produce and release NGF. Furthermore, airway epithelial
cells produce and release NGF. A number of these cells express the high-affinity receptor
for NGF, trkA; e.g. sensory neurons containing substance P (SP), T-cells, B-cells,
macrophages and mast cells.
Many inflammatory cells express a high affinity NGF receptor: monocytes (30, 38,
54), mast cells (55), basophils (56), macrophages (57), T-cells (50, 58) and B-cells
(59, 60). NGF shows various effects in inflammatory models. This could be
relevant in relation to allergic asthma (reviewed in 46). Indeed, NGF promotes
inflammatory mediator release from basophils (56), mast cells (54, 62), T- and B-
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cells (1, 50, 63), eosinophils (52) and macrophages (64). Furthermore, NGF
induces antibody synthesis and secretion from B cells (63), induces differentiation
of monocytes into macrophages (65) and is an autocrine survival factor that rescues
macrophages (57). NGF has several effects on mast cells: it attracts mast cells (66),
induces phenotypic switching of the mast cells (67) and changes the expression of
cytokines (68).
Role of NGF in inflammatory pain
The role of NGF has been studied extensively in relation to inflammatory pain
(69). A local rise in NGF is found in inflammatory pain (69, 70). Furthermore,
hyperalgesia  can be induced by simply applying NGF locally (71, 72). In
inflammatory models, decreasing the amount of available NGF with the use of
antibodies reduces inflammatory pain (70, 73-76). Most pain studies suggest that
NGF induces pain by an increased release of substance P (15, 77, 78).
Furthermore, the number of trkA immunoreactive neurons is enhanced in a model
for inflammatory chronic pain (79). Only a few studies suggest a role for NGF in
inflammatory pain by affecting immune cell function (73), involving changes in
mast cell function (69, 70).
We postulate that similar mechanisms involving NGF in inflammatory pain could
play a role in the inflammation in the airways in allergic asthma. The tachykinin
substance P induces constriction of the smooth muscle in the airways (6, 80, 81),
increase of vascular permeability (14, 80, 82) and have an effect on immune cell
function, such as activating and changing the function of mast cells (83-85).
Hypothesis on a role for NGF in the asthmatic disease
We postulate a role for NGF in the induction of allergic asthma. We hypothesize
that NGF can affect airway function by changing the properties of the sensory
nerves in the airways. In order to reveal the role of NGF in asthma, we first studied
the effect of NGF on airway function (chapter 2). Thereafter we performed a more
mechanistic approach to analyze whether sensory nerve endings are involved in
effects of NGF on airway function (chapter 3). Furthermore, we studied the role of
NGF in an allergic model of asthma. In chapter 4 the influence of NGF on acute
bronchoconstriction induced by allergen challenge is documented. In chapter 5 this
is followed by a study on the influence of NGF on airway hyperresponsiveness,
inflammation and increase in substance P containing nerves 24 hrs after allergen
challenge. In chapter 6  we speculate on the presumed communication between
mast cells and sensory neurons in this respect. In the discussion (chapter 7) we
summarize and speculate on mechanisms by which NGF could play a role in the
asthmatic disease.
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Abstract
Since asthmatic patients show increased nerve growth factor (NGF) serum levels,
we examined the effect of NGF on airway function. Intravenously administered
NGF potentiates the histamine-induced bronchoconstriction with a maximum of
over 200% in anesthetized spontaneously breathing guinea pigs. Doses of 8 ng and
80 ng NGF per kg body weight induce a significant hyperresponsiveness to
histamine. NGF itself does not affect airway reactivity. Airway
hyperresponsiveness is observed 30 min and 3 hr after NGF administration, and
has disappeared after 24 hr. The neurokinin-1 receptor antagonist SR 140333
completely blocks the NGF-induced hyperresponsiveness, pointing to a role for
tachykinins. This is the first report showing a direct relation between peripherally
administered NGF and airway hyperresponsiveness. Taking into consideration that
plasma NGF levels have been shown to be elevated in asthmatic patients, our result
points to an important role for NGF in the pathogenesis of asthma.
Introduction
NGF is a member of the neurotrophin family of proteins that can regulate neuronal
development, maintenance, and recovery from injury. NGF has been extensively
studied in relation to neurite outgrowth. However, it now becomes clear that NGF
also plays a crucial role in inflammation (1).
Inflammation can lead to an enhanced production and release of NGF.
Inflammatory mediators, including interleukin-1, interleukin-4, interleukin-5,
tumor necrosis factor α, and interferon-γ have been shown to induce the release of
NGF (2, 3). In addition to neurons, non-neuronal cells, such as mast cells (4),
fibroblasts (2) and epithelial cells (5) are able to synthesize NGF.
NGF affects immune cell activity, as it promotes inflammatory mediator release
from basophils (6), mast cells (7, 8), T- and B-cells (9-11) and macrophages (12).
NGF is also able to sensitize neurons and induce an enhanced production of
Substance P and other tachykinins (13, 14). An enhanced innervation of
predominantly sensory nerves, producing Substance P, can be found in the airways
of transgenic mice overexpressing NGF in the airways (15). An enhanced
expression of tachykinin mRNA in the nodose ganglia in a guinea pig model for
asthma has been shown as well (16). Previously, we have shown a role for
tachykinins in the development of airway hyperresponsiveness in the guinea pig
(17, 18).
Recently, increased levels in serum NGF were found in asthmatic patients (19).
Airway inflammation and hyperresponsiveness are characteristic features in the
asthmatic disease (20), and NGF seems to be a possible mediator in these events.
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Therefore, we investigated whether NGF can induce airway hyperresponsiveness
and whether tachykinins are involved.
Methods
Lung function measurement
Male Hartley guinea pigs (400-600 g; Harlan CPB, Zeist, The Netherlands) were
anesthetized with urethane (2 g/kg body weight intraperitoneally). Lung function
was measured in spontaneously breathing guinea pigs, essentially after Amdur and
Mead (21). Air flow and tidal volume were determined by cannulating and
connecting the trachea via a Fleisch flow head (Meijnhart, The Netherlands) to a
pneumotachograph. A pressure transducer (MP45-2; Validyne Engineering Corp.,
Northridge, CA) measured the transpulmonary pressure by the difference between
the tracheal cannula and an oesophagal cannula. In this way pulmonary resistance
(RL) was determined breath by breath by dividing transpulmonary pressure by
airflow at isovolumetric points. RL values were averaged per three breaths and are
presented as actual value. A small polyethylene catheter (PE-50) was placed in the
right jugular vein for intravenous administration of different compounds. Animal
studies were approved by the Animal Care Committee of the Utrecht University.
Materials
In the present study we used the precursor of NGF, murine NGF 7S (Sigma
Chemical Co., St. Louis, MO and Alomone Labs, Jerusalem, Israel) in the guinea
pig, as all neurotrophic factors are highly conserved in different species (22). NGF
was administered intravenously at doses of 0.8, 8 or 80 ng per kg body weight.
NGF was injected 30 min, 3 or 24 hr before starting airway function measurement.
The airway resistance was measured in the anesthetized guinea pig upon
intravenous administration of increasing doses of histamine. The dose-response
curve lasted 30-40 minutes. The neurokinin-1 receptor antagonist SR 140333 (23),
2 µg per kg body weight (kindly provided by Sanofi Recherche, Montpellier,
France) was administered intravenously 10 min before the injection of 8 ng NGF
per kg body weight. Pilot experiments revealed that 2 µg SR 140333 per kg body
weight completely blocked the substance P-induced decrease in blood pressure in
the anesthetized guinea pig (data not shown). In control animals, instead of NGF or
SR 140333, vehicles were administered; saline containing 0.01 % bovine serum
albumine and saline containing 1 % ethanol, respectively.
Statistics
Means and standard error of the mean (SEM) were calculated. P-values were
determined using an unpaired Student’s t-test for the comparison of two means.
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For multiple comparisons of single means an analysis of variance (ANOVA)
followed by Bonferroni's test was used. Probability values of P<0.05 were
considered significantly different.
Results


























Figure 1. Induction of airway hyperresponsiveness to histamine by NGF. NGF (8 ng per kg
body weight) or vehicle was administered 30 min before administration of increasing doses
of histamine (intravenously). Bars represent mean ± SEM (n=5 per group). * p<0.05
control vs. NGF-treated, Student's t-test.
A strong hyperresponsiveness (an increase in contractile response) to histamine
was found 30-70 min after injection of 8 ng NGF per kg body weight (fig. 1). The
airway resistance after the highest dose of histamine (20 µg per kg body weight)
increased significantly from 2.3 ± 0.3 cm H2O/ml/sec in the control animals to 6.0
± 0.6 cm H2O/ml/sec in the NGF-treated animals (P<0.01). NGF did not induce
any change in airway resistance by itself (basal resistance 0.10 ± 0.02 cm
H2O/ml/sec in control animals and 0.13 ± 0.01 cm H2O/ml/sec in NGF (8 ng per kg
body weight) animals.
The effect of NGF on airway responsiveness to histamine was dose-dependent (fig.
2). Administration of 0.8 ng NGF was without effect on the histamine-induced
increase in airway resistance, whereas 80 ng NGF induced an airway
hyperresponsiveness equal to 8 ng NGF.
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Figure 2. Effect of different doses of NGF on airway responsiveness. Saline and three
different doses of NGF, 0.8 ng, 8 ng, or 80 ng NGF per kg body weight, were administered
30 min before administration of increasing doses of histamine. Only the airway resistance
to the highest dose of histamine, 20 µg histamine per kg body weight, is depicted. Bars
represent mean ± SEM (n=14 for pooled controls, n=4/5 for NGF-treated animals).
* P<0.01 control vs. NGF treated, Student's t-test.
A significant increase in airway responsiveness could still be found 3 hr after the
injection of NGF (fig. 3). Maximum values were 2.8 ± 0.6 cm H2O/ml/sec in saline
and 5.4 ± 0.4 cm H2O/ml/sec in NGF-treated animals (P<0.01). Histamine induced
increases in airway resistance were no longer different from control animals 24 hr
after the intravenous injection of NGF.
The neurokinin-1 receptor antagonist SR 140333 was able to completely inhibit the
NGF-induced airway hyperresponsiveness (fig. 4).
Discussion
Asthmatic patients show a highly elevated level of serum NGF (19). This is the
first study showing a rather acute increase of airway responsiveness to histamine
after a single, peripheral, injection of NGF. Therefore, we postulate a role for NGF
in the development of asthma. The induction of airway hyperresponsiveness by
NGF was dose-dependent as 8 ng and 80 ng NGF per kg body weight caused a
significant increase in airway responsiveness, whereas no effect was found using
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the lower dose of 0.8 ng NGF. NGF showed an increase on airway responsiveness
within 30 min to 3 hr after the administration, whereas no increase could be
determined 24 hr after a single injection of 8 ng NGF.
























Figure 3. Effect of a single injection of NGF on the airway responsiveness measured at
different time points. A single dose of NGF (80 ng per kg body weight) was administered
30 min, 3 hr, or 24 hr before administration of the doses of histamine. Only the airway
resistance to the highest dose of histamine, 20 µg histamine per kg body weight, is
depicted. Bars represent mean ± SEM (n=15 for pooled controls, n=4/5 for NGF-treated
animals). * P<0.02 control vs. NGF treated, Student's t-test
NGF is able to augment neurogenic inflammation (24), and this could be one of the
mechanisms via which airway hyperresponsiveness was induced. It is known that
NGF changes the properties of sensory nerve endings by inducing a very fast
accumulation of second messenger in synaptosomes (25), by sensitizing the nerve
terminal (24) or by altering neuropeptide levels in sensory nerves (14). Previous
studies, in our and other groups, have shown a role for tachykinins in the IL-5 (17),
13-hydroxyoctadecadienoic acid (18), ozone (26), and citric acid (27) induced
airway hyperresponsiveness in animal models. Moreover, tachykinin levels are
elevated in asthmatics (28), and protective effects of neurokinin receptor
antagonists have been reported (29). In this study we show that the NGF-induced
airway hyperresponsiveness is mediated via the neurokinin-1 receptor. The
preferred ligand for the neurokinin-1 receptor is substance P; however, there is also
a relative high affinity for neurokinin A (28).
Two receptors are known for NGF: the low-affinity receptor p75 neurotrophin
receptor and the high-affinity tyrosine kinase receptor A (trkA). Upon contact NGF
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binds to the trkA receptor and in a tyrosine kinase-dependent manner
phosphorylates key transduction-related proteins or ion channels, thereby
sensitizing the peripheral sensory nerve ending (25, 30). Alternatively, the NGF-
trkA complex is internalized and retrogradely transported to the nucleus, where the
preprotachykinin mRNA levels (precursor for substance P and neurokinin A) and
protein levels (substance P and neurokinin A) are altered (14, 31). The p75 low-
affinity NGF receptor is also shown to be responsible for an upregulation in
tachykinin content in sensory nerves (32). Any of these mechanisms could account
for an increased release of substance P, presumably from the sensory nerve
endings, and thereby induction of airway hyperresponsiveness. The NGF-induced
neuronal sensitization could also be indirect, via the release of sensitizing
mediators from trkA expressing inflammatory cells, e.g. mast cells and monocytes
(7, 24, 30).
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Figure 4. Effect of the neurokinin-1 receptor antagonist SR 140333 on the NGF-induced
airway hyperresponsiveness. Vehicle or SR 140333 were administered intravenously 10
min before saline or NGF. Saline or NGF (8 ng per kg body weight) were administered 30
min before administration of increasing doses of histamine. Bars represent mean ± SEM
(n=4/5 per group). * P<0.05 vehicle-NGF vs. SR 140333-NGF and vs. vehicle-saline,
ANOVA followed by Bonferroni's test.
In conclusion, this study shows a clear role for the neurokine NGF in developing
airway hyperresponsiveness to histamine. Asthmatic patients show an elevated
level of serum NGF (19). This suggests a possible relationship between the high
NGF serum levels and the pathological situation in asthmatic patients. In the
guinea pig 8 - 80 ng NGF per kg body weight (approximately 25 ml blood in a 500
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g weighing guinea pig) induced an airway hyperresponsiveness (fig. 2). The dose
range in which NGF caused an airway hyperresponsiveness, was comparable to the
serum levels NGF found in asthmatic patients: 150 pg NGF/ml serum (19). In
several animal models for pain, neutralizing antibodies against NGF have been
proven to attenuate the pathological changes due to inflammation or NGF (19, 33,
34) and even the increased levels of substance P (35). Thus, NGF might be a new
target for therapy in asthma.
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Abstract
Administration of nerve growth factor (NGF) induces airway hyperresponsiveness
in guinea pigs in vivo, as shown in the previous chapter. A receptor antagonist for
the tachykinin neurokinin-1 receptor can prevent this hyperresponsiveness. We
further investigated the role of sensory nerves in the NGF-induced airway
hyperresponsiveness.
We used isolated tracheal rings from guinea pigs to measure tracheal contractility.
In these rings sensory nerve endings are present but lack any contact with their cell
bodies. In this in vitro system NGF dose-dependently induced a tracheal
hyperresponsiveness to histamine. The neurokinin-1 receptor antagonist SR140333
blocked the induction of tracheal hyperresponsiveness to NGF in this isolated
system. This suggested a role for the tachykinin substance P, possibly derived from
sensory nerve endings. To investigate the role of sensory nerve endings we used
the cannabinoid receptor 1 (CB1) agonist R-methanandamide to inhibit excitatory
events at the nerve terminal. The CB1 receptor agonist indeed blocked the tracheal
hyperresponsiveness to NGF in the isolated system as well as the airway
hyperresponsiveness in vivo.
Our results indicate that NGF acts by increasing substance P release from sensory
nerve endings, which in turn induces airway hyperresponsiveness in guinea pigs.
Introduction
The neurotrophin NGF is a newly studied mediator in relation to allergic disease
such as asthma (1-3). In humans with allergic diseases such as rhinoconjunctivitis,
urticaria-angioedema and asthma circulating NGF levels are increased (4). In the
study of Bonini and colleagues (4), NGF serum levels were particularly high in
patients with allergic asthma. An increase in the neurotrophins NGF, brain-derived
neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) in bronchoalveolar lavage
fluids after allergen challenge is reported in patients with asthma (2). In patients
with allergic rhinitis a very fast increase in NGF in the nasal lavage fluids is
already observed 10 min after allergen challenge (5). Furthermore, allergen
challenge induced an increase in NGF levels in bronchoalveolar lavage fluid of
sensitized mice (3).
Inflammatory mediators, including interleukin-1, interleukin-4, interleukin-5,
tumor necrosis factor α, and interferon-γ induce the release of NGF (6, 7). In
addition to neurons, also non-neuronal cells such as mast cells (8), fibroblasts (6),
T-cells (9), eosinophils (10) lymphocytes (11) and airway epithelial cells (12),
synthesize NGF. NGF shows various properties in inflammatory models, which
could be interesting in relationship to allergic asthma as well (reviewed in 13).
chapter 3
33
NGF affects immune cell activity, as it promotes inflammatory mediator release
from basophils (14), mast cells (15, 16), T- and B-cells (9, 17, 18) and
macrophages (19). Furthermore, NGF induces antibody synthesis and secretion
from B cells (18), attracts mast cells (20) and induces differentiation of monocytes
into macrophages (21). One study focussed on the role of NGF in the development
of allergic asthma. Application of antibodies directed against NGF in a mouse
model for allergic asthma can prevent T cells shifting to Th2 cells, a hallmark of
allergy (3).
Furthermore, NGF is able to sensitize neurons and induce an enhanced production
of substance P and other tachykinins in sensory nerves (22, 23). Tachykinins play a
role in neurogenic inflammation and in the development of airway
hyperresponsiveness and asthma (24, 25). We showed recently that administration
of NGF induced airway hyperresponsiveness in guinea pigs (1). The neurokinin-1
receptor antagonist SR140333 prevented this hyperresponsiveness. This points to a
role for substance P, the preferred ligand of the neurokinin-1 receptor (1).
The present study focuses on the role of sensory nerves in NGF-induced airway
hyperresponsiveness. For that purpose, we used a tissue preparation containing
sensory nerve endings, without any contact with their cell bodies to elucidate the
involvement of sensory nerve endings versus the neuronal cell body.
Methods
Materials
We used the precursor of NGF, murine NGF 7S (Alomone Labs, Jerusalem,
Israel), dissolved in saline containing 0.01% bovine serum albumine. The
neurokinin-1 receptor antagonist SR140333 (26) was kindly provided by Sanofi
Recherche (Montpellier, France); it was dissolved in saline containing 1% ethanol.
Pilot experiments revealed that SR140333 completely blocked the substance P-
induced contraction in the isolated tracheal rings (data not shown). R-
methanandamide (Tocris Cookson Ltd., Langford, UK) was used to activate the
CB1 receptor and was dissolved in saline containing 1% ethanol. CB1 receptor
stimulation inhibits neuropeptide release (31).
Animals
Male Hartley guinea pigs (400-600 g; Harlan CPB, Zeist, The Netherlands) were
used in all experiments. The Animal Care Committee of the Utrecht University
approved the animal studies.
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In vitro organ bath studies
To isolate the tracheal rings (3 cartilage segments per ring), the animals were killed
by an overdose of pentobarbital (Apharmo, Duiven, The Netherlands)
intraperitoneally. Tracheal rings were immediately placed in an isometric organ
bath set-up. The baths contained heated (37 °C) Krebs solution (containing: NaCl
6.9 g/l, NaHCO3 22.1 g/l, glucose monohydrate 1.65 g/l, KCl 0.35 g/l, KH2PO4
0.16 g/l, MgSO4∙7H2O 0.29 g/l, CaCl2∙2H2O 0.37 g/l) which was gassed with 95%
O2 / 5% CO2. The experiment started with four washout periods, lasting 15 min
each. During these washouts a tension was applied of 2000 mg, 2000 mg, 4000 mg
and 2000 mg, respectively. A histamine concentration response curve (10-8 M – 10-
3 M) was subsequently conducted to measure contractility of the tracheal rings.
NGF was applied at concentrations of 0.2, 2 and 20 ng/ml 30 min before the start
of the histamine concentration response curve. SR140333 (3x10-6 M) and R-
methanandamide (1x10-7 M) were applied 10 min before addition of NGF to the
organ bath.
In vivo lung function measurement
Guinea pigs were anesthetized with urethane (2 g/kg body weight
intraperitoneally). Lung function was measured in spontaneously breathing guinea
pigs, essentially after Amdur and Mead (27). Airflow and tidal volume were
determined by cannulating and connecting the trachea via a Fleisch flow head
(Meijnhart, The Netherlands) to a pneumotachograph. A pressure transducer
(MP45-2; Validyne Engineering Corp., Northridge, CA) measured the
transpulmonary pressure by the difference between the tracheal cannula and an
esophageal cannula. In this way airway resistance (RL) was determined breath by
breath by dividing transpulmonary pressure by airflow at isovolumetric points. RL
values were averaged per three breaths and are presented as actual value. A small
polyethylene catheter (PE-50) was placed in the right jugular vein for intravenous
administration of R-methanandamide, NGF and histamine.
One dose of NGF was injected 30 min before the start of the lung function
measurement, preceded by the administration of R-Methanandamide (0.5 µg/ kg
body weight) or its vehicle 10 min earlier. The airway resistance was measured in
the anesthetized guinea pig upon intravenous administration of increasing doses of
histamine. The dose response curve lasted 30-40 min.
Statistics
Means and standard error of the mean (SEM) were calculated. For concentration or
dose response curves a two way ANOVA was performed. Probability values of P <
0.05 were considered significantly different.
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Figure 1. NGF concentration-dependently induces a hyperresponsiveness to histamine in
tracheal rings in vitro. A concentration of 0.2 ng/ml NGF (n=9) 30 min before the start of a
concentration response curve did not enhance contractility (A), whereas concentrations of 2
ng/ml NGF (n=6) (B) and a concentration of 20 ng/ml (n=5) (C) did induce a tracheal
hyperresponsiveness (n=16 for all vehicles). For B and C * P<0.0001 NGF vs. vehicle.
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Results
NGF applied to the organ bath 30 min before the start of a concentration response
curve induced a tracheal hyperresponsiveness to histamine (fig. 1). The increase in
reactivity was dependent on the concentration of NGF. A concentration of 2 and 20
ng/ml enhanced contractions to histamine (P<0.0001), whereas 0.2 ng/ml did not
significantly enhance the contractility of the tracheal rings. At the highest
concentration of histamine (10-3 M) 2 ng/ml NGF increased the contraction from
2391 ± 196 to 3354 ± 543 mgf and 20 ng/ml NGF resulted in an even higher
contraction of 4808 ± 930 mgf.
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Figure 2. Addition of SR140333 (3x10-6 M) 40 min before start of a histamine
concentration response curve in the organ bath prevents the hyperresponsiveness of the
tracheal rings induced by NGF (2 ng/ml) added 30 min before start of the concentration
response curve (n=12). * P<0.0001 saline-NGF vs. saline -vehicle; # P<0.0001 SR140333 -
NGF vs. saline-NGF.
A preincubation of 10 min with the neurokinin-1 receptor antagonist SR140333
inhibited this NGF induced tracheal hyperresponsiveness (fig. 2, P<0.0001). R-
methanandamide,a CB1 receptor agonist, blocked the NGF-induced tracheal
hyperresponsiveness as well (fig. 3, P<0.0001). A 10 min preincubation with R-
methanandamide reduced the maximal contraction with NGF from 3058 ± 304 to
2262 ± 163 mgf. SR140333 or R-methanandamide did not affect the contractility
of control rings (figs. 2 and 3).
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Figure 3. Addition of R-methanandamide (1x10-7 M) 40 min before start of a histamine
concentration response curve in the organ bath prevents the hyperresponsiveness of the
tracheal rings induced by NGF (2 ng/ml) added 30 min before start of the concentration
response curve (n=9-16). *P<0.0001 saline-NGF vs. saline-vehicle; #P<0.0001
methanandamide-NGF vs. saline-NGF.
Intravenous administration of NGF induces an airway hyperresponsiveness to
histamine in vivo (fig. 4). This airway hyperresponsiveness, observed after
administration of 80 ng/kg body weight NGF, was completely prevented by
pretreatment with R-methanandamide (fig. 4, P<0.0001). Pretreatment with R-
methanandamide reduced NGF-induced airway resistance at the highest dose of
histamine from 4.9 ± 0.6 to 2.3 ± 0.3 cm H2O/ ml / sec. Neither NGF nor R-
methanandamide induced a change in basal airway resistance (data not shown).
Discussion
NGF induced an airway hyperresponsiveness to the contractile agonist histamine,
as measured in isolated tracheal rings in an organ bath set-up (fig. 1). In this
preparation sensory nerve endings lack contact with their cell bodies. Our results
imply that contact of the sensory nerve endings with their cell bodies is not
necessary for the development of tracheal hyperresponsiveness induced by NGF.
Interestingly, the neurokinin-1 receptor antagonist SR140333 blocked NGF-
induced tracheal hyperresponsiveness (fig. 2). This points to a role for the preferred
ligand of the neurokinin-1 receptor, the tachykinin substance P. Substance P is
predominantly released from sensory nerve endings (24). However, cells like
monocytes, macrophages, leukocytes and T-cells are also able to synthesize and
release substance P (28, 29).
Sensory nerve endings are essential in NGF-induced airway hyperresponsiveness
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Figure 4. R-methanandamide (0.5 µg/kg body weight) 10 min prior to 80 ng NGF/kg body
weight completely prevents the NGF-induced airway hyperresponsiveness (n=5-6).
* P<0.0001 saline-NGF vs. saline-vehicle; # P<0.0001 methanandamide-NGF vs. saline-
NGF.
A prominent role for the sensory nerve ending in the NGF-induced effects is
confirmed by our results with R-methanandamide. This CB1 receptor agonist (30)
also prevented NGF-induced tracheal hyperresponsiveness (fig. 3). CB1 receptors
are almost exclusively present on sensory nerve endings; their stimulation inhibits
neuropeptide release (31). One study on CB1 receptors in the airways shows that
alveolar Type II cells also express the CB1 receptor (32). However, these cells do
not produce substance P and therefore a role of these alveolar cells in the induction
of airway hyperresponsiveness is unlikely. R-methanandamide also completely
prevented the induction of airway hyperresponsiveness by NGF in vivo (fig. 4.).
This effect of R-methanandamide in vivo could be via central pathways, affecting
responses in the brain stem or central nervous system. However, Richardson and
colleagues demonstrated that not the central CB receptors but rather the peripheral
CB1 receptors mediate inhibition of hyperalgesia (33). This study on hyperalgesia
suggests, like our study, that the effect of CB1 receptor is mediated via the
inhibition of neurosecretion from sensory nerve endings. Recently, endogenous
cannabinoids, like anandamide, have been shown to be full agonists for vanilloid
receptor-1, when applied at doses of 10-100 µM (34, 35). Therefore, R-
methanandamide may have interacted with the vanilloid receptor-1 in our set-up.
However, R-methanandamide is weaker as an activator of the vanilloid receptor-1
than anandamide (1/10 ratio; 36, 37). Therefore it is unlikely that R-
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methanandamide (0.1 µM) would act via the vanilloid receptor-1 in the present
study.
NGF is known to bind to its high affinity tyrosine kinase receptor A (trkA);
thereafter the NGF-trkA complex is internalized and retrogradely transported to the
nucleus, where the preprotachykinin mRNA levels (precursor for substance P and
neurokinin A) and protein levels (substance P and neurokinin A) are enhanced (23,
38). The p75 low affinity NGF receptor is also involved in the upregulation in
tachykinin content in sensory nerves (39). Hoyle and colleagues (40) showed that
transgenic mice, over-expressing NGF in the airways, develop a hyperinnervation
of the airways and an increased content in substance P. Other studies reported that
long term NGF exposure induces upregulation of substance P in sensory nerves,
though this was not studied in the airways (e.g. 40, 41). It is generally agreed that
protein synthesis occurs in the neuronal cell body, followed by axonal transport to
the nerve endings (although very few studies have reported on the role of RNA in
axons, 43). Therefore, in the tracheal preparation in our study presented here, an
upregulation of substance P content can be excluded, as the nerve endings lacked
contact with their cell bodies. Moreover, the administration of NGF can induce an
airway hyperresponsiveness in vivo within one hr, a time period we think is too
short for protein synthesis, axonal transport and subsequent release of substance P
(1). Taken together, this implies there is a clear difference between the long term
effects of NGF and the influence of NGF within approximately one hr. Therefore,
shortly after NGF application, presumably other mechanisms than substance P
upregulation are responsible for the changes induced by NGF.
NGF did not change basal tone in the tracheal rings and application of histamine,
as a stimulus, was needed to reveal a tracheal hyperresponsiveness induced by
NGF. This implies that NGF did not induce release of contractile mediators by
itself. In the present study, either an increase in release of substance P or a change
in neurokinin-1 receptor functioning can underlie the changes in contractility. In
favor of a change in function of sensory nerve endings, and thereby an increase in
substance P release, are the findings with CB1 receptor agonist. Furthermore, a
very recent abstract by Zhou and colleagues reported a long-term (24-48 hrs)
increase in substance P release in tracheal explants in response to NGF (44),
thereby confirming the role of the nerve ending.
NGF is known to change the properties of sensory nerve endings by inducing a
very fast accumulation of second messenger in synaptosomes (45), by sensitizing
the nerve terminal (46) by inducing protein kinase C translocation to the membrane
(47). Besides this, NGF binding to the TrkA in a tyrosine kinase-dependent manner
induces phosphorylation of key transduction-related proteins or ion channels,
thereby also sensitizing the peripheral sensory nerve ending (45, 48). NGF
increases the response of the vanilloid receptor-1 to capsaicin in 10 min, at the
same concentrations (2-100 ng/ml NGF) as used in our study (49). The vanilloid
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receptor-1 is the receptor for the perception of heat, protons and for the agonist
capsaicin. These stimuli are able to induce release of tachykinins from the sensory
nerve endings (34, 35, 49). Since there is presumably no endogenous ligand
present in our organ bath for the vanilloid receptor, activation of this receptor in
our experiments is not very likely. Taken together, this suggests that more down-
stream mechanisms in receptor signaling must be affected. In the same view, the
CB1 receptor agonist inhibiting excitatory processes at the nerve terminal (31)
blocks NGF induced tracheal hyperresponsiveness (figs. 3 and 4). Still, the
increase in contractility in the tracheal rings due to NGF can also be due to an
upregulation in the number or affinity of neurokinin-1 receptors. The NGF-induced
neuronal sensitization could be direct, as described above, or indirect, via the
release of sensitizing mediators from trkA expressing inflammatory cells, such as
mast cells and monocytes (15, 38, 46, 48).
Therefore, we hypothesize a general lowering of the threshold for activation of the
sensory nerve endings due to short-term exposure to NGF, which induces a
tracheal and airway hyperresponsiveness to histamine.
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Abstract
Intravenous administration of nerve growth factor (NGF) to guinea pigs results in
airway hyperresponsiveness within 1 hr, as we have demonstrated before. In the
present study we documented the involvement of NGF in the acute allergic airway
response.
Guinea pigs that are sensitized to ovalbumin show an acute bronchoconstriction
directly after challenge with ovalbumin. Intra-tracheal application of 10 µg
antibodies directed against NGF (anti-NGF) one hr before the challenge reduces
the acute severe bronchoconstriction to approximately 40% and the sustained
bronchoconstriction to approximately 20% of the reaction in controls. This shows a
high potency of anti-NGF in diminishing the direct bronchoconstriction.
Inhibition of the tyrosine kinases of the tyrosine kinase receptor A, the high-
affinity receptor for NGF, has no effect on the bronchoconstriction. Therefore we
postulate that the p75, the low-affinity receptor for neurotrophins, is responsible
for the acute bronchoconstriction.
Our findings suggest a role for NGF in the induction of the acute asthmatic
reaction. These findings offer a new potential therapeutic strategy for the treatment
of asthma.
Introduction
NGF is a member of the neurotrophin family of proteins that regulate neuronal
development, maintenance, and recovery from injury. NGF has been extensively
studied in relation to neurite outgrowth. However, NGF can also play a crucial role
in inflammation (1).
Inflammation leads to an enhanced production and release of NGF. Inflammatory
mediators, including interleukin-1, interleukin-4, interleukin-5, tumor necrosis
factor α, and interferon-γ have been shown to induce the release of NGF (2, 3). In
addition to neurons, non-neuronal cells such as mast cells (4), fibroblasts (2), T-
cells (5) and epithelial cells (6) are able to synthesize NGF.
NGF affects immune cell activity, as it promotes inflammatory mediator release
from basophils (7), mast cells (8, 9), T- and B-cells (5, 10, 11) and macrophages
(12). NGF is also able to sensitize neurons and induce an enhanced production of
substance P and other tachykinins in sensory nerves (13, 14). Tachykinins play a
role in neurogenic inflammation and in the development of airway
hyperresponsiveness and asthma (15, 16). Furthermore, we showed that a
neurokinin-1 receptor antagonist blocked NGF induced airway




Interestingly, circulating NGF levels are increased in humans with allergic diseases
(rhinoconjunctivitis, urticaria-angioedema, asthma, (18). In the study of Bonini and
colleagues, NGF serum levels were particularly high in patients with allergic
asthma (18). Also, allergen challenge induces an increase in NGF levels in
bronchoalveolar lavage fluid of sensitized mice (19). Moreover, allergen
provocation induces an increase in NGF levels in nasal lavage fluid in patients with
allergic rhinitis (20).
NGF can interact with two receptors: either the low-affinity receptor p75, which
can also bind other neurotrophic factors such as brain derived neurotrophic factor
and neurotrophin 3, or the tyrosine kinase receptor A (trkA). Of these two
receptors, only the trkA is linked to tyrosine kinases for its signal transduction. So
far, no data are available on the receptors for NGF and their function in the
airways.
In a previous study we have demonstrated that intravenous administration of NGF
to guinea pigs results in airway hyperresponsiveness, indicating a role for NGF in
the development of one of the symptoms of the asthmatic disease (17). These
findings prompted us to further investigate the role of NGF in allergic asthma. We
tested the effects of an antibody directed against NGF and an inhibitor of the




Male Hartley guinea pigs (weighing approximately 400 g; Harlan CPB, Zeist, The
Netherlands) were sensitized to ovalbumin, grade V (SIGMA, St. Louis, MO) by
injections of a gel containing 20 µg ovalbumin/ml, and 200 mg Al(OH)3/ml as
adjuvant. Six injections were placed: one injection of 0.5 ml intraperitoneally, one
of 0.1 ml nuchally, two injections of 0.1 ml axillarly, and two of 0.1 ml inguinally.
Control animals were not sensitized and received instead a vehicle gel, not
containing ovalbumin.
Measurement of acute bronchoconstriction
Fourteen days after the sensitization procedure, the guinea pigs were individually
placed in a box to measure airway function before and after ovalbumin challenge.
Each challenge consisted of a 2 sec nebulization of 0.01% ovalbumin in sterile
saline (Ultra-Neb 2000, Devilbiss, Sommerset, PA). All animals received the
ovalbumin challenge.
The airway function of the unrestrained guinea pigs was measured using whole
body plethysmography (BUXCO, Sharon, CT) as previously described by
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Hamelmann and colleagues (21). As parameter of airway function the enhanced
pause (Penh) was determined. The Penh closely reflects the changes in pulmonary
resistance during bronchoconstriction (21). As suggested by Drazen and colleagues
(22), we inspected the barometric plethysmograph pressure tracings and assured
ourselves that the pressure variations corresponded to those from which the Penh
parameter was derived. After 5 min of measuring base line airway function,
challenge with ovalbumine was performed.
Application of anti-NGF and tyrosine kinase inhibitor
Treatment with anti-NGF or tyrosine kinase inhibitor took place 1 hr before
ovalbumin challenge, similar to Fryer and colleagues (23). The guinea pigs were
treated intra-tracheally with 10 µg anti-NGF dissolved in 50 µl saline (anti human
β-NGF, R & D Systems, Minneapolis, MI) or with 10 µg IgG isotype control
antibody (IgG goat, SIGMA). The polyclonal antibody directed against human β-
NGF was raised in the goat and purified (IgG fraction) by affinity chromatography.
A dose of 0.1 µg/ml neutralizes 5 ng/ml NGF. For treatment with tyrphostin
AG879 (Calbiochem Novabiochem, Läufelfingen, Switzerland), 200 µl of 0.2 mM
tyrphostin AG879 was applied intra-tracheally. Control animals recieved the
vehicle: saline containing 2% DMSO. Tyrphostin AG879 is an inhibitor specific
for the tyrosine kinases on the trkA (24).
In order to apply the solutions intra-tracheally, the guinea pigs were anesthetized
with halothane (2% halothane, 0.4 l/min O2, 2 l/min N2O, approximately 15-30
sec). The animals all regained consciousness within 30 sec after this procedure.
Animal studies were approved by the Animal Care Committee of the Utrecht
University.
Statistics
Means and standard error of the mean (SEM) were calculated. P-values were
determined using an unpaired two-tailed Student’s t-test for the comparison of two
means. Probability values of P<0.05 were considered significantly different.
Results
Ovalbumin challenge in sensitized guinea pigs resulted in an increase in Penh that
started about 3 min after the ovalbumin challenge and which resulted in a maximal
Penh between 5 and 10 min. after the challenge. The maximal Penh rose above
values of 20, which is comparable to the bronchoconstriction induced by more than




Figure 1. Typical Penh traces in time after allergen challenge. Sensitized guinea pigs were
challenged with ovalbumin at time=0. Animals had been were treated with IgG control
antibody (upper panel) or with anti-NGF (lower panel).
Anti-NGF prevented the severe and sustained bronchoconstriction induced by the
ovalbumin challenge (fig. 1). Treatment with anti-NGF showed a rapid decline to a
low and stable Penh after reaching no peak at all or a very low peak Penh, whereas
in the control antibody treated guinea pigs the peak Penh was much higher and
decreased more slowly (fig. 1). The area under the curve was diminished greatly by
the anti-NGF treatment. In the typical curves (fig. 1), the area under the curve
measured form 0 to 20 min after allergen challenge declined from 33.4 to 11.7
arbitrary values. Measurement of the area under the curve for the whole group was
not possible, as 2 of the control animals showed an extreme bronchoconstriction
and had to be taken out of the equipment. This indicates that the inhibitory effect of
anti-NGF is even more pronounced since none of the animals treated with anti-
NGF showed such a severe bronchoconstriction.
Peak Penh was significantly diminished by application of anti-NGF (fig. 2). The
peak for non-sensitized animals was 0.34 ± 0.04 (n=4), whereas ovalbumin
challenge in ovalbumin-sensitized and control antibody treated animals lead to an
increase to 14.60 ± 3.30 (n=4). Anti-NGF reduced the peak to 5.98 ± 1.92 (n=5,
P<0.03 anti-NGF vs. control antibody). Treatment with anti-NGF diminished
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bronchoconstriction as compared to control antibody treatment, not only when
comparing peak bronchoconstriction, but also when comparing the sustained
bronchoconstriction at 5, 10 and 15 min after the allergen challenge (fig. 2).










Figure 2. Treatment with anti-NGF one hr before ovalbumin challenge reduces the acute
bronchoconstriction. Bronchoconstriction is shown at peak, 5 min, 10 min, and 15 min after
ovalbumin challenge. Controls are non-sensitized animals (open bars), IgG and anti-NGF
are guinea pigs sensitized to ovalbumin, treated with either the control IgG antibody (solid
bars) or anti-NGF (grey bars), respectively (n=4/5). Bronchoconstriction is expressed as
Penh. * P< 0.03, anti-NGF vs. IgG, Student’s t-test.
Pre-treatment with the tyrosine kinase inhibitor tyrphostin AG879 did not affect
the acute bronchoconstriction induced by allergen challenge, making involvement
of this messenger in this process rather unlikely (fig. 3).
Discussion
Antibodies directed against NGF inhibited the duration of the severe and sustained
bronchoconstriction to allergen challenge (fig. 1 and 2). The Penh value was
largely reduced as well at several time points after the ovalbumin challenge (fig.
3). This inhibitory effect indicates a beneficial effect of anti-NGF on the duration
and magnitude of the severe bronchoconstriction.
Locally applied anti-NGF one hr before allergen challenge markedly reduced the
bronchoconstriction; this strongly suggests that a rapid local release of NGF took
place. Increased levels of NGF have been reported in relation to allergic responses
several times. In patients suffering from allergic asthma an enhancement in NGF
levels in serum (18) as well as in bronchoalveolar lavage is reported (25, 26).
Allergen challenge in patients with allergic rhinitis leads to an acute increase in
NGF in nasal lavage fluid (27). The NGF increase is also seen in an animal model:
in sensitized mice, levels of NGF are enhanced in the bronchoalveolar lavage 24
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hrs after allergen challenge (19). However, before challenge NGF levels in
sensitized mice are equal to control animals (19). This implies, that allergen
challenge is necessary for NGF upregulation. The increase in NGF serum levels in
patients suffering from allergic asthma could be due to a constant exposure to
allergens in their environment. As allergen challenge is presumably necessary for
NGF increases (19), we suggest that NGF is released immediately after allergen
challenge. Supporting this view, is the strong inhibitory effect of anti-NGF applied
only one hr before allergen challenge reported here. Furthermore, a large variety of
cells that are able to release NGF, such as eosinophils, airway epithelium, mast
cells, basophils, T-cells and fibroblasts (2, 4-7, 28) are present in the airways, and









Figure 3. Treatment with tyrphostin AG879 one hr before ovalbumin challenge does not
reduce the acute bronchoconstriction. The peak bronchoconstriction is shown after
ovalbumin challenge. All guinea pigs are sensitized to ovalbumin and are challenged with
ovalbumin. ‘Control’ refers to animals which are treated with vehicle whereas ‘AG879’
refers to animals treated with tyrphostin AG879 (n=5 for both groups). Bronchoconstriction
is expressed as Penh.
In our previous study, we showed that intravenously administered NGF induces an
airway hyperresponsiveness within 1 hr (17). Probably substance P plays a role in
NGF-induced airway hyperresponsiveness, since a neurokinin-1 receptor
antagonist was able to prevent airway hyperresponsiveness (17). Few studies have
been published on the involvement of tachykinins in acute allergic responses in the
airways. Antigen-induced microvascular leakage revealed a role for substance P in
the early allergic response (29). Recently it was shown that toluene diisocyanate
induces a rapid increase of substance P; 1 hr after inhalation of toluene
diisocyanate the number of substance P immuno-reactive nerve fibres was already
increased (30). We postulate that stimulaton of the sensory neurons by NGF could
modulate the allergen-induced bronchoconstriction in our present study.
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Confirming this idea is the enhancing effect of NGF on the release of tachykinins
from sensory nerve endings by capsaicin (31).
We further demonstrated that inhibition of the tyrosine kinases of the trkA did not
influence the acute bronchoconstriction induced by allergen challenge (fig. 3).
NGF can bind to either the trkA, the high-affinity receptor for NGF, which is
specific for NGF, or to the p75, the low-affinity receptor for NGF and other
neurotrophic factors (32). We hypothesize that the p75 mediates  the effects of
NGF in the development of the acute allergic response. So far, no studies report on
p75 or trkA function in the airways.
In addition to an acute allergic reaction and airway hyperresponsiveness, allergic
asthma causes airway inflammation (33). In other models, the involvement of p75
has been revealed in relation to inflammation. Inflammation induced an up-
regulation of p75 in inflamed tissues, suggesting that NGF, or other neurotrophic
factors such as brain derived neurotrophic factor or neurotrophin 3, participate in
NGF-induced hyperalgesia via p75 (34).
NGF is involved in airway hyperresponsiveness, a characteristic feature of asthma
(17). In our present study we show that NGF also plays a crucial role the cascade
of events leading to an acute bronchoconstriction due to allergen challenge,
possibly via the p75, a receptor for neurotrophic factors. This indicates that NGF is
involved in the early events of an acute allergic reaction. Therefore, we
hypothesize a regulatory role for NGF in both acute allergic responses as well as in
the induction of airway hyperresponsiveness. This offers a new potential approach
for the treatment of asthma.
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Abstract
We studied the involvement of NGF and its high-affinity receptor in the
development of airway hyperresponsiveness and pulmonary inflammation in a
model for allergic asthma. Ovalbumin challenge induced an airway
hyperresponsiveness after 24 hrs in ovalbumin-sensitized guinea pigs. This
coincided with an increase in the amount of NGF in bronchoalveolar lavage fluid.
Simultaneously, an increase in the percentage of substance P immunoreactive
neurons in the nodose ganglia and an increase in the amount of substance P in lung
tissue were found. We used tyrosine kinase inhibitors to block the signal
transduction of the high-affinity NGF receptor, tyrosine kinase A (trkA). Treatment
with specific tyrosine kinase inhibitors (K252a or tyrphostin AG879) inhibited the
development of airway hyperresponsiveness and prevented the increase in
substance P in the nodose ganglia and lung tissue completely. Similar treatment
with antibodies directed against NGF (anti-NGF) did not reduce the airway
hyperresponsiveness and partially inhibited increases in both the percentage of
substance P immunoreactive neurons and the amount of substance P in lung tissue.
Neither treatment with K252a, tyrphostin AG879 or anti-NGF changed the influx
of inflammatory cells in the bronchoalveolar lavage fluid due to allergen challenge.
We conclude that high-affinity receptor for NGF, trkA, plays a role in the
induction of airway hyperresponsiveness in our model for allergic asthma.
Furthermore, substance P derived from sensory nerves seems to mediate the
NGF-induced effects.
Introduction
Nerve growth factor (NGF) is a member of the neurotrophin family of proteins that
can regulate neuronal development, maintenance, and recovery from injury. NGF
has been extensively studied in relation to neurite outgrowth. However, it now
becomes clear that NGF also plays a crucial role in inflammation (1).
Inflammation can lead to an enhanced production and release of NGF.
Inflammatory mediators, including interleukin-1, interleukin-4, interleukin-5,
tumor necrosis factor α, and interferon-γ have been shown to induce the release of
NGF (2, 3). In addition to neurons, non-neuronal cells, such as mast cells (4),
fibroblasts (2), T-cells (5), eosinophils (6), lymphocytes (7), macrophages (8, 9)
and airway epithelial cells (10) are able to synthesize NGF.
An increase in circulating NGF levels is found in humans with allergic diseases
like rhinoconjunctivitis, urticaria-angioedema and asthma (11). In the study of
Bonini and colleagues (11), NGF serum levels are particularly high in patients with
allergic asthma. Allergen provocation causes an increase in NGF levels also in
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nasal lavage fluid of patients with allergic rhinitis (12). Furthermore, allergen
challenge induces an increase in NGF levels in bronchoalveolar lavage fluid of
sensitized mice (13).
NGF affects immune cell activity, as it promotes inflammatory mediator release
from basophils (14), mast cells (15, 16), T- and B-cells (5, 13, 14) and
macrophages (19). NGF is also able to affect neuronal function and to induce an
enhanced production of Substance P and other tachykinins (16,17). Tachykinins
play a role in neurogenic inflammation and in the development of airway
hyperresponsiveness and asthma (22, 23). In a previous study we have
demonstrated that administration of NGF to guinea pigs results in airway
hyperresponsiveness, which is a hallmark of the asthmatic constitution (24).
Taken together, this indicates that NGF may play a role in allergic reactions in the
airways. This prompted us to investigate whether NGF is indeed involved in the
development of airway hyperresponsiveness and pulmonary inflammation in
allergic asthma. NGF can interact with two receptors: either the trkA that binds
NGF with high affinity, or the low-affinity receptor p75, which can also bind brain
derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and NT-4. Of these
receptors, only trkA uses tyrosine kinases for its signal transduction (reviewed in
21). We tested the effects of an antibody against NGF and specific tyrosine kinase
inhibitors on ovalbumin-induced airway hyperresponsiveness and influx of
inflammatory cells into the lungs in sensitized guinea pigs. Simultaneously, we
measured levels of NGF in bronchoalveolar lavage fluid and determined the
number of substance P containing nerves in the nodose ganglia as well as the
amount of substance P in the lung tissue.
Materials and Methods
Animal model
Male Duncan Hartley guinea pigs (weighing approximately 400 g; Harlan CPB,
Zeist, The Netherlands) were sensitized to ovalbumin, grade V (SIGMA, St. Louis,
MO) by injections of a gel containing 20 µg ovalbumin/ml, and 200 mg
Al(OH)3/ml as adjuvant. Six injections were placed: one injection of 0.5 ml intra-
peritoneally, one of 0.1 ml nuchally, two injections of 0.1 ml axillarly, and two of
0.1 ml inguinally.
Fourteen days after the sensitization procedure, the guinea pigs were challenged
with ovalbumin. The animals received an intra-peritoneal injection with the
histamine H1 receptor antagonist, pyrilamine (10 mg/kg body weight; SIGMA), 30
min before allergen challenge to prevent asphyxsal collapse. Each challenge
consisted of a nebulization of 0.01% ovalbumin in sterile saline (Ultra-Neb 2000,
Devilbiss, Sommerset, PA) for 1 min in a box in which the animals had been
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placed individually. The animals were observed closely and we assured ourselves
that the guinea pig did respond to the challenge. If not, an extra challenge that
lasted for 30 sec – 1 min was given.
Control animals were either not sensitized and received a vehicle gel, not
containing ovalbumin, and subsequently challenged with ovalbumin, or were
sensitized with ovalbumin and subsequently received nebulized saline instead of an
ovalbumin challenge.
For the measurements of NGF in the bronchoalveolar lavage fluid and substance P
in neurons and lung tissue, a separate group of female guinea pigs (200-250 g body
weight, Charles River Wiga, Kreislegg, Germany) with an alternative sensitization
procedure was used. These guinea pigs were sensitized by an injection of 1 ml
containing 10 mg ovalbumin and 50 mg Al(OH)3 intraperitoneally at days 1, 14,
and 28. Control animals received the same injections without ovalbumin. At day
35, sensitized and control animals were exposed to the allergen by nebulization of
10 ml ovalbumin solution (0.1%) for 60 min in a chamber (pari-boy type 37.00,
pari-Werk GmbH, Starnberg, Germany; ref. 26). Data obtained from this model for
allergic asthma are presented in figure 4 only. The changes in substance P were
similar in this guinea pig model for allergic asthma when compared to the other
model described in this materials and methods section (see results section).
Treatment with antibodies and tyrosine kinase inhibitors
One hr before and six hrs after the ovalbumin challenge, the ovalbumin-sensitized
guinea pigs were treated with either antibodies directed against NGF or tyrosine
kinase inhibitors or their vehicles. The control animals were treated with 100 µl
saline.
For anti-NGF antibodies, either rabbit anti mouse (SIGMA; 4.7 mg protein/100 µl)
or goat anti human (R & D Systems, Minneapolis, MI); 10 µg protein/50 µl) NGF
antibodies were applied intra-nasally or intra-tracheally. The treatment with anti-
NGF effectively diminished the acute bronchoconstriction after allergen challenge
(see chapter 4). Rabbit serum (SIGMA) or goat IgG (SIGMA) were used as
controls, respectively.
Two different tyrosine kinase inhibitors were used, K252a (Calbiochem
Novabiochem, Läufelfingen, Switzerland) and tyrphostin AG879 (Calbiochem
Novabiochem). Both are specific inhibitors of the tyrosine kinases on the trkA (22,
23). Both were dissolved in saline containing 2% DMSO. We applied 100 µl of 0.1
mM K252a or 200 µl of 0.2 mM tyrphostin AG879 intra-nasally, whereas saline
containing 2% DMSO was used as a control.
In order to apply the solutions intra-nasally or intra-tracheally, the guinea pigs
were anesthetized using halothane (2% halothane, 0.4 l O2/min, 2 l N2O/min,





The airway resistance was measured 24 hrs after the ovalbumin challenge in the
anesthetized guinea pigs upon intravenous administration of increasing doses of
histamine (OPG, Zeist The Netherlands) or methacholine (Janssen Chimica,
Beerse, Belgium). For this purpose, guinea pigs were anesthetized with urethane (2
g/kg body weight intraperitoneally). Lung function was measured in spontaneously
breathing guinea pigs, essentially after Amdur and Mead (29). Air flow and tidal
volume were determined by cannulating and connecting the trachea via a Fleisch
flow head (Meijnhart, The Netherlands) to a pneumotachograph. A pressure
transducer (MP45-2; Validyne Engineering Corp., Northridge, CA) measured the
transpulmonary pressure by the difference between the tracheal cannula and an
esophageal cannula. In this way, airway resistance was determined breath by
breath by dividing transpulmonary pressure by air flow at isovolumetric points.
Airway resistance values were averaged per three breaths and are presented as
actual value. A small polyethylene catheter (PE-50) was placed in the right jugular
vein for intravenous administration of histamine or methacholine.
Bronchoalveolar lavage
After completion of the dose-response curve, the lungs were lavaged three times
through the tracheal cannula with 10 ml aliquots warmed (37 ºC) saline. Total
amount of bronchoalveolar lavage cells was counted using a Burker-Türk chamber.
For differential cell counts, cytospin preparations were stained with Diff-Quick
(Merz & Dade, Dudingen, Switzerland). Cells were identified into mononuclear
cells, lymphocytes, neutrophils and eosinophils by standard morphology.
NGF was measured in bronchoalveolar lavage fluid obtained 24 hrs after allergen
challenge from animals treated according to the alternative sensitization protocol
using a commercial ELISA kit from R&D Systems.
Immunohistochemistry
Nodose ganglia were obtained from the guinea pigs 24 hrs after allergen challenge
directly after finishing lung function measurement, or just 24 hrs after allergen
challenge when the alternative sensitization protocol was used . Zamboni-fixed
sensory ganglia were rinsed in 0.1 M phosphate buffer and cryoprotected with 18
% sucrose in phosphate buffer overnight. Sections of the sensory ganglia were cut
on a cryostat (500 OM Microm, Waldorf, Germany) at 10 µm and air dried for 30
min. Sections were incubated with a blocking solution containing 1% bovine serum
albumin and 10% normal swine serum in phosphate buffer for 60 min, followed by
an overnight incubation with a monoclonal rat antibody against substance P
(1:1000, Boehringer Ingelheim, Ingelheim, Germany). After washing in phosphate
buffered saline, a biotinylated anti-rat-immunoglobulin from sheep (Amersham,
Uppsala, Sweden, dilution 1:50) was applied for 1 hr. After several washes in
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phosphate-buffered saline, sections were incubated with a mixture of streptavidin-
Texas-Red-conjugate (Amersham, dilution 1:50). Slides were washed thoroughly
in phosphate-buffered saline and covered with coverslips with buffered glycerol
(pH 8.6). For microscopic evaluation, slides were coded and randomly two sections
were chosen and in each section 100 neurons were examined for their substance P
immunoreactivity.
Radioimmunoassay
Lung samples were obtained at the same moment from the same animals as
sensory ganglia. Samples of peripheral lung were snap frozen in liquid nitrogen.
Substance P radioimmunoassay was performed as described previously by
McGregor and colleagues (30).
Statistics
Means and standard error of the mean (SEM) were calculated. P-values were
determined using a two-tailed unpaired Student’s t-test for the comparison of two
means, unless stated otherwise.































Figure 1. Effect of tyrosine kinase inhibitors K252a and tyrphostin AG879, administered
one hr before and six hrs after allergen challenge, on airway hyperresponsiveness 24 hrs
after allergen challenge. Airway responsiveness was measured in vivo in guinea pigs upon
administration of increasing doses of histamine. Negative control = non-sensitized and
ovalbumin challenged, vehicle treated; K252a and AG879 = ovalbumin-sensitized and
challenged, K252a or tyrphostin AG879 treated; positive control = ovalbumin-sensitized





Airway hyperresponsiveness to histamine was found 24 hrs after the ovalbumin
challenge in ovalbumin-sensitized guinea pigs as compared to non-sensitized
animals. The ovalbumin-sensitized animals showed an increased responsiveness at
the histamine dose of 8 µg/kg and all higher doses (p<0.05, fig. 1). Treatment with
K252a or tyrphostin AG879 could prevent the hyperresponsiveness to histamine
after ovalbumin challenge. Thus, the animals treated with these tyrosine kinase
inhibitors did not show a significant increase in airway responsiveness at any
concentration of histamine (fig. 1). Treatment with antibodies directed against
NGF (anti-NGF) did not reduce the hyperresponsiveness to histamine (positive
control airway resistance at highest dose of histamine 4.85 ± 1.44, vs. anti-NGF
3.99 ± 1.34 cm H2O/ml/sec, both groups n=6, P>0.05).



























Figure 2. Effect of anti-NGF, administered one hr before and six hrs after allergen
challenge, on airway hyperresponsiveness 24 hrs after allergen challenge. Airway
responsiveness was measured in vivo in guinea pigs upon administration of increasing
doses of methacholine. Negative control = ovalbumin-sensitized and vehicle challenged,
control antibody treated; anti-NGF = ovalbumin-sensitized and challenged, anti-NGF
treated; positive control = ovalbumin-sensitized and challenged; n=5-6 per group. * P<0.02
anti-NGF and positive control vs. negative control.
In our ovalbumin animal model, an airway hyperresponsiveness is not only
observed for histamine, but also for other contractile agonists; this resemblesthe
asthmatic disease. We therefore tested airway responsiveness to the cholinergic
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receptor agonist methacholine as well. Ovalbumin induced an increased airway
responsiveness to methacholine in ovalbumin-sensitized animals 24 hrs after
ovalbumin challenge as compared to vehicle challenge (fig. 2). The airway
resistance at a methacholine dose of 20 µg/kg body weight increased from 8.64 ±
1.43 (vehicle challenged) to 16.05 ± 1.31 cm H2O/ml/sec (ovalbumin challenged,
control antibody treated; P<0.02). Treatment with anti-NGF did not reduce this
hyperresponsiveness either (airway resistance was 19.61 ± 2.68 cm H2O/ml/sec at a
methacholine dose of 20 µg/kg body weight).





total cell count in
bronchoalveolar lavage fluid
negative control - + 19.4 ±   3.4
positive control
(control antibody IgG)
+ + 49.5 ±   6.9  *
anti-NGF + + 73.2 ± 10.2  *
positive control
(vehicle)
+ + 65.3 ± 19.3  *
K252a + + 44.9 ±   4.1  *
AG879 + + 46.6 ± 11.7  *
* = P<0.03 vs. negative control
Bronchoalveolar lavage
The airway hyperresponsiveness coincided with an influx of cells in the
bronchoalveolar lavage fluid (table 1). The percentage of eosinophils increased in
ovalbumin-sensitized animals as compared to non-sensitized animals due to
allergen challenge (from 11% ± 3.2 in non-sensitized to 43.6% ± 6.0 in sensitized
animals, P<0.001, fig. 3). Neither the total amount of cells in the bronchoalveolar
lavage fluid nor the percentage of eosinophils was affected by treatment with anti-
NGF, K252a or tyrphostin AG879 (table 1 and fig. 3). The percentages of
lymphocytes, neutrophils and macrophages were not affected by treatment with
anti-NGF, K252a or tyrphostin AG879 (data not shown).
NGF levels were enhanced in bronchoalveolar lavage fluid in sensitized animals as
compared to non-sensitized animals 24 hrs after allergen challenge (fig. 4 A). NGF
































Figure 3. The percentage of eosinophils of the bronchoalveolar lavage (BAL) cells did not
change 24 hrs after allergen challenge by anti-NGF or tyrosine kinase inhibitor treatment.
Treatment with either respective vehicles (positive control), anti-NGF, K252a or tyrphostin
AG879 took place one hr before and six hrs after allergen challenge. * = P<0.001 all groups
vs. negative control.
Substance P
The number of substance P immunoreactive neurons was counted in the ganglia of
the same animals that were used to determine NGF levels in bronchoalveolar
lavage fluid. The percentage of substance P immunoreactive neurons in the nodose
ganglia was augmented in sensitized animals as compared to non-sensitized
animals 24 hrs after allergen challenge: from 22 ± 2 to 43 ± 4 % (P<0.0003, fig. 4
B). At the same time, the substance P content of lung tissue was increased as well:






































































Figure 4. (A) The amount of NGF was elevated in bronchoalveolar lavage fluid (* P<0.03,
one-tailed Students t-test), and (B) the number of substance P immunoreactive neurons in
nodose ganglia was increased (* P<0.0003), as well as (C) the amount of substance P in
lung tissue (* P<0.0002) 24 hrs after ovalbumin challenge in ovalbumin-sensitized animals
(ovalbumin, n=3) as compared to non-sensitized animals (control, n=5).
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A similar increase, as present in guinea pigs sensitized following the alternative
sensitization procedure, was found in the guinea pigs, which were used for lung
function measurements. The percentage substance P immunoreactive neurons in
the nodose ganglia increased from 24.6 ± 1.8 to 44.2 ± 2.6 % and 46.0 ± 2.5
(P<0.01) for antibody and vehicle positive controls, respectively (fig. 5). The
substance P content in the lung increased from 250 ± 33 to 519 ± 38 and 484 ± 12
pmol/g wet weight (P<0.04) for antibody and vehicle positive controls,
respectively (fig. 6).



























Figure 5. The percentage of substance P immunoreactive neurons in nodose ganglia
increased after allergen challenge and this increase was partially inhibited by anti-NGF and
completely blocked by tyrosine kinase inhibitor treatment. Treatment with either control
serum and anti-NGF or vehicles, K252a and tyrphostin AG879 took place one hr before
and six hrs after allergen challenge. All groups n=4-5. * P<0.01 anti-NGF and positive
controls vs. negative controls, # P<0.01 anti-NGF, K252a and AG879 vs. respective
positive control.
The guinea pigs that were treated with the tyrosine kinase inhibitors, revealed a
complete inhibition of the increase in the percentage of substance P
immunoreactive neurons: from 46.0 ± 2.5 to 29.0 ±1.1 for K252a and to 28.2 ± 2.7
% for tyrphostin AG879 (P<0.01, fig. 5). A similar decrease was seen when
measuring substance P content in the lung tissue: from 484 ± 12 to 262 ± 74 for
K252a and to 292 ±43 pmol/g wet weight for tyrphostin AG879 (P<0.02, fig. 6).
Treatment with anti-NGF induced a decline but did not completely prevented the
increase in the percentage of substance P immunoreactive neurons or the amount of
substance P in lung tissues of sensitized animals as compared to the non-sensitized
animals (figs. 5 and 6). The precentage of substance P immunoreactive neurons
was down-regulated from 44.2 ± 2.6 to 33.3 ± 1.7 % by treatment with anti-NGF
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(P<0.01), and the substance P content in lung tissue was decreased from 519 ± 38
to 360 ± 32 pmol/g wet weight (P<0.02). However, when compared to the negative
controls, the number of substance P immunoreactive neurons was still increased
(P<0.01) as was the substance P content (P<0.04).






























Figure 6. Substance P concentration in the lung tissues increased after allergen challenge.
This increase was partially reduced by anti-NGF treatment. It was completely prevented by
tyrosine kinase inhibitor treatment. Treatment with either control serum or anti-NGF or
vehicles, K252a and tyrphostin AG879 took place one hr before and six hrs after allergen
challenge. All groups n=5 * P<0.004 anti-NGF and positive controls vs. negative control, #
P<0.02 anti-NGF, K252a and AG879 vs. respective positive control.
Discussion
Guinea pigs sensitized to ovalbumin showed an airway hyperresponsiveness to
histamine and methacholine 24 hrs after allergen challenge (figs. 1 and 2). Specific
inhibition of the trkA tyrosine kinases by the inhibitors K252a and tyrphostin
AG879 inhibited the development of airway hyperresponsiveness. Apparently, the
inhibition of the down-stream signaling of the trkA receptor did effectively prevent
induction of airway hyperresponsiveness. The importance of the trkA in long-term
inflammatory processes is confirmed by the enhanced numbers of trkA
immunoreactive neurons in a model for inflammatory chronic pain (31). We
conclude that the trkA receptor is involved in the development of airway
hyperresponsiveness in our model for allergic asthma.
The cellular influx in the airways in this allergic asthma model was not affected by
interfering with trkA. Therefore, the possible involvement of NGF in the airway
function of allergic guinea pigs can be envisioned as being distal to inflammatory
cell influx into the airways.
NGF is the neurotrophic factor with the highest binding affinity for trkA (25).
Interestingly, the development of airway hyperresponsiveness in this model of
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allergic asthma coincided with an increase in NGF levels in bronchoalveolar
lavage fluid 24 hrs after allergen challenge (fig. 4 A). Possibly, NGF originates
from the infiltrating inflammatory cells. Indeed, NGF formation has been
demonstrated in various immune organs including the spleen, lymph nodes, and
thymus, and immune cells such as mast cells, eosinophils, and B- and T-cells (32).
Increases in the levels of NGF in the airways have been reported before in
sensitized mice 24 hrs after allergen challenge (13) and in allergic asthmatic
patients after allergen challenge (33). It is unknown which cells are the major
source for NGF in the airways. Sanico and colleagues recently showed a rapid
increase in NGF in nasal lavage fluids shortly after allergen provocation in patients
with allergic rhinitis (12). The authors suggest mast cells as most likely source of
NGF.
As shown before, guinea pigs sensitized to and challenged with ovalbumin display
an increase in substance P immunoreactive neurons in the nodose ganglia,
however, not in jugular or dorsal root ganglia (26, 34). In our present study, we
found a similar increase was found  in substance P immunoreactive neurons in the
nodose ganglia (fig. 4 B) as well as an increase in substance P content in the lung
tissue (fig. 4 C). There was a correlation between the increase of NGF in
bronchoalveolar lavage fluid and the increase of substance P in lung tissue
(r2=0.625, P<0.02, n=8). Therefore, it is likely that NGF is the important mediator
for the induction of increased levels of in substance P. This is confirmed by Hunter
and colleagues, who showed that tracheal application of NGF can increase the
percentage of substance P immunoreactive neurons in nodose ganglia (35).
Substance P containing fibers in guinea pig airways are C-fibers, whereas neurons
with Aδ-fibers are normally not containing substance P. NGF induced the
formation of substance P in nodose neurons with Aδ-fibers. The increase is similar
to the increase in substance P in nodose ganglion neurons with Aδ-fibers in allergic
models (26, 34, 35).
Interestingly, the tyrosine kinase inhibitors inhibited the increases in substance P
immunoreactive neurons and substance P content in the lung tissue (fig. 5 and 6).
Furthermore, increases in substance P together with induction of airway
hyperresponsiveness have been reported before; for instance in models using
toluene diisocyanate (36), ozone (37) or citric acid (23) to induce changes in
airway function. Furthermore, our group has shown a role for tachykinins in the
IL-5 (38) and 13-hydroxyoctadecadienoic acid (39) induced airway
hyperresponsiveness in animal models. Moreover, tachykinin levels are elevated in
patients with asthma (22), and protective effects of neurokinin receptor antagonists
have been reported (40). Anti-NGF did not completely prevent substance P
increases in this model for allergic asthma. This may be the reason that airway
hyperresponsiveness was not prevented by anti-NGF treatment.
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NGF acts on a variety of cells of the immune system, including mast cells,
eosinophils, and B- and T-lymphocytes (41). Inhibiting trkA signaling did not
affect the number of cells; however, it could have affected the activity of the cells
in the airways and thus lowering the pathologic effects of the allergic
inflammation. For instance, mast cells function could have been altered as mast
cells express trkA (42) and NGF has been shown to induce phenotypic switching
of the mast cells (43) and change the cytokines that are expressed (44). NGF can
activate eosinophils (6) as well as T-cells (5) via trkA. Therefore the tyrosine
kinase inhibitors could have affected their activation state. Furthermore, there is a
role for NGF as an autocrine survival factor that rescues macrophages (9).
We hypothesized a beneficial effect on allergic airway pathology of antibodies
directed against NGF for several reasons. Firstly, NGF is upregulated after allergen
challenge in our guinea pig model (fig. 4 A) as well as in mice (13), as in patients
with allergic asthma or allergic rhinitis (12, 13, 33). Furthermore, inhibiting trkA
prevented the induction of airway hyperresponsiveness, and NGF is the preferred
ligand for trkA. In line with this is our previous finding that administration of NGF
results in an airway hyperresponsiveness (24). However, using antibodies against
NGF did not inhibit the development of airway hyperresponsiveness. In our
experimental conditions, the same amount of anti-NGF effectively diminished
acute bronchoconstriction, after allergen challenge (chapter 4); this implies that the
amount of anti-NGF is sufficient to block effects mediated by NGF in the guinea
pig airways. The fact that anti-NGF did not reduce airway hyperresponsiveness in
our guinea pig model is in contrast with the findings of Braun and colleagues, who
did demonstrate a reduction in airway hyperresponsiveness by treatment with
antibodies directed against NGF (13). The latter attenuation by anti-NGF of airway
responsiveness was obtained in mice; therefore species difference may account for
the different effects of anti-NGF.
Interestingly, the increased percentage of substance P immunoreactive neurons and
the increase in substance P content in the lung tissue were down-regulated by anti-
NGF. However, the inhibition was not complete: there was still a significant rise
both in the percentage of immunoreactive neurons for substance P as well as in the
amount of substance P in the lung tissue (figs. 5 and 6). These data suggest that an
increase in substance P levels changed the airway responsiveness; indeed, the
tyrosine kinase inhibitors blocked the increase of substance P (figs. 5 and 6) and of
airway hyperresponsiveness (fig. 1). This again points to a causal relationship
between increases in substance P and the development of airway
hyperresponsiveness.
The partial inhibition by anti-NGF of increases of substance P and the lack of
effect of anti-NGF on ovalbumin-induced airway hyperresponsiveness could be
explained by the action of NT-3. NT-3 is elevated in bronchoalveolar lavage fluid
after allergen challenge in patients with allergic asthma (33). NT-3 can also bind
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trkA, although with lower affinity than NGF (45). NT-3 could activate trkA and
thereby cause airway hyperresponsiveness without influence of antibodies directed
against NGF. Furthermore, NT-3 can induce substance P release (46).
NGF induces airway hyperresponsiveness, as we showed before (24). IN the
present study, we showed that the high affinity receptor for NGF, trkA, is involved
in the development of airway hyperresponsiveness and in the concomitant
increases in substance P 24 hrs after allergen challenge. Antibodies directed against
NGF did not prevent the induction of airway hyperresponsiveness after allergen
challenge; possibly because anti-NGF did not completely block substance P
increases.
We conclude that NGF plays a role in the induction of airway
hyperresponsiveness, in our model for allergic asthma through its high affinity
receptor trkA. Furthermore, substance P derived from sensory nerves might
underlie the NGF-induced effects. This is in accordance with our previous data that
showed that NGF induces airway hyperresponsiveness via the neurokinin-1
receptor. Presumably, NGF is not the only neurotrophin underlying airway
hyperresponsiveness.
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Abstract
We presume nerve growth factor (NGF) released by mast cells underlies functional
changes in sensory nerves in our animals models for asthma, since mast cells are
found in close proximity of sensory nerves. In this study we used primary cultures
of both cell types to investigate possible functional interactions. Sensory neurons
were derived from embryonic dorsal root ganglia and mast cells were cultured
from bone marrow-derived cells. We observed adherence of the mast cells to the
neurites, whereas normally these mast cells are in suspension during culture. No
functional gap junctions were found between mast cells and neurons. The presence
and stimulation of mast cells induced small enhancements in the expression of
preprotachykinin (PPT) mRNA, the precursor for tachykinins such as substance P
and neurokinin A, in the dorsal root ganglion neurons. No expression of PPT
mRNA was found in mast cells, suggesting that the mast cells do not synthesize
PPT and, subsequently, no tachykinins. Presence of the dorsal root ganglion
neurons generated minor alterations in the capability of the mast cells to
degranulate.
We conclude that mast cells adhere to neurons and small functional changes in
mast cells and neurons due to co-culturing and stimulation were found. Excreted
factors could underlie interaction between these two types of cells.
Introduction
Mast cells are found in close proximity to neurites (1, 2). These neurites are mostly
of sensory origin (1, 3, 4). Sensory neurons express several peptides, the
tachykinins, and are sensitive to capsaicin (5, 6). Sensory neurons are involved in
neurogenic inflammation, for example in the asthmatic disease (7), neuropathic
pain (8) and inflamed skin (9). Neurogenic inflammation involves changes in
function of the sensory neurons due to inflammatory mediators which results in an
enhanced release of tachykinins from the nerves (7). The role of mast cells in
hypersensitivity reactions is well known, by its activation with allergen and IgE
(10). However, mast cells may play a role in the phenomenon of neurogenic
inflammation as well by affecting nerve function (2, 4, 11). Indeed, mediators
released from mast cells have been suggested to affect neuronal function. These
mediators include arachidonic acid metabolites, serotonin, nitric oxide, nerve
growth factor and histamine (4, 12, 13). Additionally, mediators released by
nerves, such as acetylcholine, NGF, substance P and ATP affect mast cell function




In most in vitro studies, single mediators, released by either neurons or mast cells,
change the properties of either mast cells (13, 14) or neurons (15, 16). In vivo
studies revealed possible interactions between both cell types (17). In mouse skin
preparations the number of close contacts between mast cells and neurons changed
depending on environmental changes (1). This indicates that mast cell-neuron
contacts might have physiological relevance. Furthermore, allergen provocation in
the airways, presumably merely activating mast cells, changes neuronal function in
the airways (18). Mucosal mast cells are activated and secrete mast cell proteases
by Pavlovian conditioning (19). This indicates that neuronal activation can directly
stimulate mast cells. Inhibiting the release of mediators from either neurons or mast
cell in vivo can prevent activation of the other (3, 20). For instance, in vivo
depletion of neuropeptides with capsaicin reduced IgE-mediated inflammatory
response; this indicates that neurons are involved in mast cell-mediated
inflammation (21).
Very few studies report on co-cultures of mast cells and neurons. Such studies are
either using two cell lines (22-24), or one cell line and primary cultured neurons
(22-25). They evidence communication between neurons and mast cells, but do not
document how this affects function and properties of either cell. In our present
study, we examined the effect of co-culturing primary derived-mast cells and
sensory neurons on functional properties of the two types of cells.
Materials and methods
Dorsal root ganglia culture
Dorsal root ganglia were removed aseptically from 16 day-old embryos of Wistar
rats (GDL, Utrecht, the Netherlands) and pooled in ice-cold L-15 medium
(GIBCO). Dorsal root ganglion neurons were cultured essentially as previously
described by Dijkhuizen and colleagues (26). Dorsal root ganglia were cervical and
thoracic of origin, which form a large percentage of NGF sensitive neurons (27,
28). These tachykinin containing nerves partly innervate the airways (29). The
dorsal root ganglia were transferred to DMEM/F-12 (mixture 3:1) medium
supplemented with 200 µg/ml transferrin, 200 µM putrescine, 40 nM
progresterone, 60 nM selenium, 10 µg/ml insulin, and 0.01% albumine (all
GIBCO). A mitotic inhibitor, 5x10-4 M cytosine-β-D-arabinofuranoside (Sigma)
prevented was added to the medium mixture, to prevent non-neuronal cells from
growing. This concentration of cytosine-β-D-arabinofuranoside prevents division
of non-neuronal cells without influencing the growth of the dorsal root ganglion
neurons (23, 30).
Single dorsal root ganglia were cultured in either six wells–plates (Costar) or in
smaller culture slides (Falcon, micronic, 8 chamber polystyrene vessel). Plates
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were coated with polyornithin (Sigma) and laminin (Boehringer Mannheim).
Cultures were grown at 37ºC in 5% CO2 humidified atmosphere.
Bone marrow-derived mast cells (BMMC)
The bone marrow of eight- to 10 weeks old BALB/c mice (GDL) was aseptically
flushed from femurs into complete RPMI. The complete RPMI contained 4 mM L-
glutamine, 50 µM mercaptoethanol, 1 mM sodium pyruvate, 100 U/ml penicillin,
100 µg/ml streptomycin and 0.1 mM non-essential amino acids (GIBCO). The cell
suspension was washed twice in complete RPMI. Fetal calf serum (10% vol/vol)
and pokeweed-stimulated spleen supernatant (20% vol/vol) were added to the
medium. Spleen single cell suspensions were activated with pokeweed at a cell
density of 2x106 cells/ml and the supernatant harvested after 6-7 days. Bone
marrow-derived cells were cultured in 75-cm² tissue culture flasks at a density of
2x105 cells/ml. Medium was refreshed every week to achieve a final concentration
of 1x105 cells/ml (essentially after Karimi and colleagues; 31, 32). After three
weeks of culture the cells developed into an essentially pure population of mucosal
type mast cells (31, 32).
Co-culture of mast cells and dorsal root ganglia
Bone marrow-derived mast cells were added to the dorsal root ganglion cultures at
the 2nd day of the dorsal root ganglion-culture. Cells were cultured in either
modified DMEM/F12 with different concentrations of NGF or a combination of
DMEM/F12 and complete RPMI. Different medium mixtures of DMEM/F12 and
complete RPMI had no effect on PPT mRNA expression in the dorsal root
ganglion-culture. Therefore we used a medium consisting of half chemically
defined medium and half mast cell medium (co-culture medium) in all co-cultures.
ß-hexosaminidase release
Beta-hexosaminidase release was used as parameter for mast cell degranulation
(31). Cells were washed in Tyrode buffer (supplemented with 2.38% HEPES, 0.1%
BSA at pH 7.2). Mast cells were added at 40.000 cells per well in a 96 flat bottom
wells plate (Costar). To investigate mast cell activation upon FCεRI crosslinking,
cells were incubated with anti-dinitrophenyl (DNP) IgE (H1DNPε 26.82
hybridoma, a kind gift from J. Riviera, NIH, USA; 20% vol/vol) at 37 °C for 1.5
hours. After washing, cells were activated by adding multivalent antigen DNP-
HSA (Sigma) at concentrations between 1-30 ng/ml and incubated for 30 min at
37ºC. To obtain total β-hexosaminidase content, cells in control wells were lysed
using 1% triton X-100. Supernatants were analyzed for β-hexosaminidase activity
by incubation with 80 µM 4-methylumbelliferyl-N-actetyl-β-D-glucosaminide
(Sigma) in citrate buffer (0.1 M, pH 4.5) for 60 min at 37ºC. Subsequently, the
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reaction was stopped by addition of 100 µl glycine buffer (0.2 M glycine, 0.2 M
NaCl, pH 10.7) and fluorescence was measured at λex: 360/ λem: 460 using a
Millipore Cytofluor 2350 microplate reader. Degranulation was calculated as the
amount of β-hexosaminidase activity present in the supernatant as a percentage of
the total β-hexosaminidase activity.
For the β-hexosaminidase experiments involving co-cultures, dorsal root ganglion
neurons were grown in the 96 wells plates. Single cell suspensions of dorsal root
ganglia were cultured in order to obtain an equal number of neurons in each well.
To derive single cells suspensions, dorsal root ganglia were incubated with 2%
collagenase type I (Sigma) for 30 min at 37°C in 5% CO2 humidified atmosphere.
Dorsal root ganglia were transferred into fresh medium, and triturated 10 times
through a flame-polished glass Pasteur pipet (modified from Lindsay; 33).
Gap junction probes
To investigate the presence of functional gap junctions, either neurons or mast cells
were loaded with a fluorescent probe. Lucifer yellow was injected into a neuronal
cell body of a co-culture in which mast cells and dorsal root ganglion neurons were
present for 3 or 4 days. Cultures were viewed microscopically with a BX50wi
fluorescence microscope (Olympus) using a water immersion objective (F1) and
using an excitation cube U-mwb (λex < 450, λem > 515). Alternatively, mast cells
were loaded with the fluorescent probe 4-(and-5)-carboxyfluorescein diacetate
(carboxyfluorescein). Cells were washed twice with RPMI and incubated at 37ºC
with 10 mM carboxyfluorescein. Subsequently, the cells were washed and added to
the dorsal root ganglion-culture at day 3 in culture. Cells were fixed with 1%
paraformaldehyde after two washes with PBS (37ºC) at 10 min, 1 hr and 2 hrs after
addition. Mounting medium (Vectashield Mounting medium, Molecular Probes)
was applied and cultures were covered with cover slides for microscopical
examination. A Nikon Eclipse E600 with Nomarski optics and epifluorescence
(filters λex: 465-495/ λem: 515-555) was used and images were recorded digitally
using an Apogee KX2 camera (Lambert Instruments B.V.).
RNA isolation and RT-PCR
Dorsal root ganglia were collected by scraping the cells off the plates, whereas
bone marrow-derived cells were spun down. Cells were rinsed with PBS and RNA
was isolated from these cells with a total RNA isolation system-kit (Promega). We
used oligo-dT of different lengths for the reverse transcriptase (RT) reaction (10
min at 22ºC, 45 min at 42ºC, 5 min at 99ºC; all products Perkin Elmer). Amplitaq
gold (Perkin Elmer) was used for the PCR which consisted of 30-40 cycles (95
ºC/60 ºC/72 ºC each one min). Rat preprotachykinin (PPT) primers were: sense 5’-
AGA GGA AAT CGG TGC CAA CG-3’ and antisense 5’-TTC GTA GTT CTG
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CAT TGC GC-3’ with 4 different product lengths; β-PPT (321 bp), γ-PPT (276bp),
α-PPT (267bp) and δ-PPT (220bp; 30). All splice variants can give rise to
substance P; β-PPT and γ-PPT can code for neurokinin A, whilst neurokinin K can
only be translated from β-PPT and neurokinin-γ merely from γ-PPT. These primers
were also suitable to detect mice PPT, though mice only have three splice variants
instead of four. Rat GAPDH primers: sense 5’-CAC GGC AAG TTC AAC GGC
AC-3’ and antisense 5’-TCT GAG TGG CAG TGA TGG CA-3’ (all Pharmacia
Biotech).
Immunocytochemistry
Dorsal root ganglion-cultures were fixed at four days in culture with 4%
paraformaldehyde in PBS and permeabilized with 100% methanol (–20 ºC for 10
min). The peroxidase reactivity was blocked for 10 min with 0.1% NaN3 and 0.3%
H2O2 in 50 mM Tris-buffer. This was followed by 3 washes with 50 mM Tris-
buffer (pH 7.6), and subsequently samples were washed for 15 min in 50 mM Tris,
135 mM NaCl at pH 7.5, with 1% horse serum (TBS-HS). Samples were incubated
with the anti-neurofilament antibody RT 97 (Boehringer Mannheim) at a
concentration of 0.5 µg/ ml in TBS-HS for 1 hr, at room temperature. Isotype
control plates were incubated with mouse anti-human thyroglobulin (Sigma, 0.5
µg/ml). The negative control consisted of TBS-HS. Cultures were washed with
TBS-HS and incubated with horseradish peroxidase (HRP) conjugated rabbit anti-
mouse antibody (Dako, 1:200 in TBS-HS) for 30 min. This was followed by three
washes with TBS-HS and three washes with 50 mM Tris-buffer, pH 7.6 and the
cultures were stained with 60% 3,3’–diaminobenzidine tetrahydrochloride (in 50
mM Tris-buffer, pH 7.6, with 0.2% (NH4)2SO4, NiSO4 and 0.02 % H2O2) for
maximally 30 min at room temperature. The culture slides were washed with 50
mM Tris-buffer. Subsequently, mast cells were stained with toluidine blue (0.5%
toluidine blue in glacial acetic acid, pH 2.7, Sigma) for 2 min. Slides were washed
with water, and air-dried slides were embedded in DPEX. Cultures were examined
microscopically using a normal light microscope and images digitized using a
video camera.
Results and discussion
Co-culture of bone marrow-derived mast cells and sensory neurons
Primary mast cell cultures normally grow in suspension. These mast cells did not
adhere to the poly-ornithin/laminin coated wells. When co-cultured with dorsal
root ganglia, mast cells specifically adhered to the neurites (fig. 1). Another study
showed close contacts between mast cells and neurites when co-culturing
sympathetic neurons and RBL-2H3 cells, a rat basophilic leukemia cell line, which
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is a model for mucosal mast cells (22). However, our present study is, to our
knowledge, the first report showing binding of mast cells to sensory neurons in a
primary culture.
Figure 1. Typical example of bone marrow-derived mast cells attached to neurites in dorsal
root ganglion-culture. Neurites are immunostained for neurofilament and mast cells are
visualized using toluidine blue. Right panel is detail of left panel.
Numerous studies show a functional and morphological relationship in vivo
between mast cells and capsaicin-sensitive sensory nerves in pig skin (35), murine
skin (1), rat intestine (17), guinea pig ileum (36), rat dura mater (3, 20) and rat and
swine airway mucosa (35, 37).
Communication between cells which are in close contact often occurs via gap
junctions. Furthermore, both neurons and mast cells express similar connexins (the
proteins forming gap junctions) namely the connexins 32 and 43 (38-40). In order
to reveal formation of gap junctions between mast cells and neurites, we applied
specific probes: either Lucifer yellow, a gap junction permeant tracer (41, 42), or
carboxyfluorescein, which is specific for detecting gap junctions (43, 44). The
dorsal root ganglia were cultured and at day 2 co-cultured with mast cells for three
days. Lucifer yellow was injected into the cell body of a neuron, and this dye was
clearly transported throughout the neurites. No fluorescence could be detected in
mast cells (data not shown). This indicated that there is no intercellular transport
from neurons to mast cells via gap junctions. In a separate set of experiments, mast
cells were labeled with carboxyfluorescein and added to a four-day dorsal root
ganglion-culture and fixed at 10 min, 1 hr and 2 hrs after addition of the mast cells.
No fluorescent dye could be detected in the neurites (fig. 2). This also indicated
that there were no functional gap junctions between mast cells and neurons.
As we did detect contacts between mast cells and neurites (fig. 1), but no
functional gap junctions (fig. 2), obviously, gap junctions are not necessary for
communication between mast cells and neurons. Instead, these cells might
Co-culturing neurons and mast cells
82
mutually affect each other by their respective mediators in a paracrine fashion (4,
12, 13). This has been suggested before, as soluble factors from RBL-2H3 cells
stimulated cooperatively the neurite outgrowth of sympathetic neurons (45).
Figure 2. Fluorescent image (left) and Komarski transformed light microscopic image
(right) of carboxyfluorescein-loaded mast cells. The carboxyfluorescein was loaded in the
mast cells, and mast cells were co-cultured with dorsal root ganglion neurons for 2 hrs.
Fluorescence was not visible in the neurites (left panel), which were present in close
proximity the mast cells, as can be seen in the right panel, indicating there are no gap
junctions formed.
Change in sensory nerves
In order to investigate whether the mast cells were able to change functional
properties of the neurons, the expression of PPT, the precursor for tachykinins,
mRNA was determined using a RT-PCR. Naive dorsal root ganglia dissected from
the embryos already expressed PPT mRNA. Increasing concentrations of NGF in
the culture medium induced enhanced expression of PPT mRNA in the
monoculture of these neurons. We found a clear increase in the expression of PPT
between 0 and 10 ng/ml NGF, whereas we did not find differences with higher
concentrations (10-200 ng/ml) of NGF. Our findings are in accordance with the
study of Lindsay and others, which also showed an increase in PPT expression
with NGF concentrations between 0 and 25 ng/ml (33). Since NGF can also be
derived from satellite cells, Schwann cells or fibroblasts present in the culture (46-
48), actual concentrations of NGF in culture could be higher than the exogenously
added NGF. Therefore, we cultured the dorsal root ganglia at 5 ng/ml NGF to
avoid a maximum increase in PPT mRNA. We did not culture the dorsal root
ganglia without NGF, thereby preventing upregulation by the very low
concentration of 5 ng/ml NGF itself, as neurons would otherwise not survive (49,
chapter 6
83
50). Withdrawal of a neurotrophic factor would induce a down-regulation in the
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Figure 3. PPT mRNA expression of dorsal root ganglion-cultures (DRG) and/or mast cells
(BMMC) in the absence or presence of antigen (Ag) and/or IgE. GAPDH was used as a
housekeeping gene. Sequential dilutions of cDNA were used for the PCR; dilutions were
the same in all conditions for PPT and GAPDH amplification, starting at an equal amount
of RNA in the RT reaction. The four arrows before PPT bands point to four different splice
variants of this precursor.
Dorsal root ganglion-cultures were maintained with 5 ng/ml NGF for 1 day. On
day 2 the mast cells were added and co-cultured with the dorsal root ganglia for
another 3 days. PPT mRNA expression of different cultures is shown in fig. 3. All
panels showed highly comparable GAPDH bands, which made it possible to
compare DNA bands for PPT directly. Four splice variants of PPT were observed
(30).
The primary cultures of mast cells showed no evidence for the production of any
substance P, as we detected no PPT mRNA in the mast cell culture (panel F, fig.
3). To our knowledge no other studies describe any data on substance P synthesis
in mast cells. Interestingly, other hemapoietic cells like monocytes, macrophages,
leukocytes and T-cells are able to synthesize and release substance P (51-53). Of
course, merely no detection of PPT mRNA by using a RT-PCR can not exclude
production of substance P at the protein level.
PPT mRNA amplification of dorsal root ganglia cultured without mast cells is
shown in panel A of fig. 3. Co-culturing of dorsal root ganglia with the primary
mast cells affected the PPT expression. The addition of unstimulated mast cells to
the dorsal root ganglion-culture, either with addition of only antigen (panel C, fig.
3) or only IgE (panel D, fig. 3) to the culture, enhanced PPT expression slightly.
PPT bands showed a higher density on the gel and PPT bands are clearly visible at
the highest dilution. The presence of stimulated mast cells to the dorsal root
ganglion-culture (panel E, fig. 3) did not further affect levels of PPT mRNA.
All changes described so far are slight changes in PPT mRNA expression. We did
not detect any PPT mRNA in mast cells; therefore we exclude that increases in
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PPT mRNA in the sensory neurons are due to PPT mRNA present in mast cells. As
a negative control for co-culturing with mast cells, dorsal root ganglion neurons
were incubated with IgE alone and this did not upregulate PPT expression (panel
B, fig.3).
Mediators, such as histamine and arachidonic acid metabolites released from
activated mast cells can affect neuronal function (4, 12). Another mediator released
from mast cells is NGF, which is able to upregulate PPT expression (54, 55). In our
present study here, we found small changes in neuronal function. It could be that
changes were actually larger, but could not be detected due to technical limitations.
Indeed, in our experiments, we used a semi-quantitative RT-PCR in which samples
are related to the amount of the housekeeping enzyme GAPDH. As not all mast
cells are washed-off before RNA isolation, due to adherence of part of the
population of mast cells to the dorsal root ganglia, this could have induced an
increase in the amount of housekeeping gene when isolating total RNA. This could
have resulted in an underestimation of expression of PPT mRNA.
Change in mast cells
Calcium mobilization occurred in mast cells when co-cultured neurons were
activated with bradykinin (24). In our study, we examined the function of the mast
cells by stimulation with IgE and antigen, and changes in function due to the
presence of the neurons. Merely very small enhancements in ß-hexosaminidase
release by the mast cells were detected as a result of co-culturing with the dorsal
root ganglion neurons (fig. 4).
Previous findings in neuron-mast cell co-cultures showed a communication
between the cells, but no change in the function of neurons or mast cells (22,
24).We expected more pronounced changes in our co-culture system of bone
marrow-derived mast cells and sensory neurons, as different mediators released
from each of these cells have pronounced effects in a mono-culture of either mast
cells or sensory neurons. Mediators released from activated mast cells, e.g.
histamine and arachidonic acid metabolites (4, 12, 16) can alter neuronal function.
Another mediator released from mast cells, NGF can induce substance P synthesis
in sensory neurons (52, 53, 57). We and others showed that substance P enhances
mast cell mediator release or stimulates the mast cell (13, 32, 57, 58). Direct mast
cell-neurite communication occurred via substance P in a co-culture of mast cells
and neurons (24). In our present study, we co-cultured neurons with mucosal mast
cells. Cultured mucosal mast cells increase responsiveness to substance P only
after addition of stem cell factor and interleukin-4 to the culture medium (32). This
could be the reason that we found only small changes in mast cell function, as we
did not add interleukin-4 or stem cell factor to the mast cell cultures. However,
whether or not substance P could induce a change in responsiveness to FcεR1
crosslinking has not been studied (32).
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Figure 4. IgE-mediated ß-hexosaminidase release as percentage of total cellular content of
ß-hexosaminidase from bone marrow-derived mast cells. Release is slightly enhanced by
co-culturing the mast cells with dorsal root ganglion neurons for 3 days. Mast cells were
cultured on poly-ornithine and lamin-coated wells with or without dorsal root ganglion
neurons. In control experiments, neurons were treated as the mast cells (incubated with IgE
and the antigen DNP-HSA) and showed a small aspecific ß-hexosaminidase release, which
was subtracted from the data obtained with the mast cells co-cultured with neurons. (n=3).
Data on exogenously applied mediators indicate that the levels of mediators
released from either mast cells or neurons in our experiments were probably not
sufficient to induce large changes in the other cell type. Indeed, only a high
concentrations of exogenous, but not endogenous, substance P are able to release
histamine from isolated human skin fragments (59). In contrast, one study showed
that activation of mast cells in co-culture with sympathetic neurons altered
neuronal physiology (60). In this study, rat peritoneal mast cells were activated
with anti-IgE in co-culture with neurons derived from mouse superior cervical
ganglia. Mast cell activation caused depolarization of the neurons and decreased
their membrane resistance (60).
In conclusion, our present study shows that mast cells adhere to neurites but that
only small functional changes could be detected when co-culturing these two types
of cells.
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Neurotrophins, in particular nerve growth factor (NGF), are recently discovered
players in the asthmatic disease (1-5). Our data presented in this thesis confirm a
role for NGF in the pathologic effects and altered airway function in a guinea pig
model for allergic asthma. In this chapter, we will discuss possible mechanisms
involved in the effects of NGF on airway function and pathology.
1. Release of NGF
Patients with allergic asthma show increases in serum levels of NGF (2). We
showed in chapter 5 that in a guinea pig model for allergic asthma, there is a rise in
NGF in bronchoalveolar lavage fluid 24 hrs after allergen challenge. This increase
in NGF in bronchoalveolar lavage fluid after allergen provocation is found as well
in mice (3), and in man (1). We are not aware of a study showing which cells are
responsible for the increase in levels of NGF. In the airways, a variety of cells are
present during allergic inflammation that can synthesize NGF: mast cells (6, 7),
fibroblasts (8), T- and B-cells (9, 10), eosinophils (11) lymphocytes (10) and
airway epithelial cells (12; see top fig. 1). NGF levels are increased shortly, within
10 min, after allergen provocation in patients suffering from allergic rhinitis (13).
The authors of this paper suggest that mast cells are a very likely source for NGF;
indeed mast cells release mediators within minutes after nasal provocation with
allergen (13). Any of the other cell types could be responsible for long-term
increases in NGF as suggested by Virchow and colleagues (1).
2. NGF and immune cells
Several studies provide evidence that NGF may play a role in neuroimmune
interactions (4). Immune cells synthesize and release NGF and NGF has several
effects on these cells (fig. 1).
2.1. Mast cells
Mast cells synthesize, store and release NGF (6, 7). Antigen-induced increass in
vagal sensory and parasympathetic activity may be a consequence of the allergic
reaction in the airways, presumably through mast cell activation (14, 15). The
factor released from the mast cells to induce changes in neuronal function could be
NGF (16). Indeed, factors released by mast cells are shown to induce neurite
outgrowth, which could almost completely be inhibited by antibodies directed
against NGF (17). Activation of rat peritoneal mast cells in co-culture with
sympathetic neurons alters neuronal physiology by inducing depolarization and
























Figure 1. Proposed model for the effects of NGF on airway function. Macrophages,
epithelial cells, B- and T-cells, eosinophils and mast cells can release NGF in an
inflammatory situation (6, 10, 12, 48). NGF levels are enhanced in the airways (1, 3, 13 and
chapter 5) leading to a change of sensory nerve function and substance P release (chapters
2, 3 and 5). This induces activation of neurokinin-1 receptors leading to airway
hyperresponsiveness.
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In several animal models for allergic asthma substance P synthesis is increased
(18-20 and chapter 5). The increase in substance P could be mimicked by
administration of NGF (22). It could be hypothesized that mast cells are the major
source for NGF in allergic models. This would imply that mast cell activation
could induce NGF release and thereby induce substance P increases. We tried to
reveal whether mast cell activation induced a change in neuronal preprotachykinin
(PPT), the precursor for tachykinins, mRNA. Minor changes were induced in
neuronal expression of PPT mRNA by mast cell co-culture and activation (chapter
6). Whether or not this is a valid reflection of an allergic situation remains a matter
of debate. Further experiments are needed to elucidate whether or not mast cells or
other cells are the major source for NGF in an allergic situation.
A close relationship exists between the increased NGF plasma values and the
number of infiltrating mast cells in vernal keratoconjunctivitis (4). This is
confirmed by a recent study revealing NGF as a chemoattractant for mast cells
(23). Several studies report effects of NGF on mast cells. A number of studies
reveal that NGF can induce differentiation of mast cells and the closely related
basophils (14, 24-28). Furthermore, NGF induces changes in expression of
inflammatory mediators: interleukin-6 (IL-6) and PGE2 are induced whereas tumor
necrosis factor α (TNFα) is inhibited (29). Furthermore, NGF induces mast cell
degranulation in vivo (30) and prevents apoptosis of mast cells (31). Inducing
differentiation, increasing inflammatory cytokines and prevention of apoptosis of
mast cells can all increase the airway pathology due to allergic inflammation.
Presumably, actions of NGF are mediated by the trkA which is expressed on mast
cells (7, 31-33). Taken together, it is very likely that NGF affects mast cells (fig.
1).
2.2. T- and B-lymphocytes
Many studies that suggest effects of NGF on T-cells, and vice versa, could be of
great interest in allergic pathologies. Allergy is characterized by T helper (Th) cells
that are of Th2 type, producing Th2 type cytokines (34, 35). Human CD4+ T cell
clones (preferentially of activated Th2 type) produce and release NGF, and express
high-affinity NGF receptors (9, 36, 37). Furthermore, Th2 type cytokines can
induce release of NGF: IL-4 (38) and IL-10 (39) induce release of NGF from
astrocytes. In contrast, the Th1-derived cytokines interferon-γ and IL-2 do not
induce NGF synthesis (39). This suggests T-cells can be a likely source of NGF in
an allergic condition besides mast cells. Likewise, in a model for multiple sclerosis
(an autoimmune disease) NGF promotes induction of Th2 type cytokines and
prevents the synthesis of Th1 type cytokines (40). NGF induces differentiation of
eosinophils, basophils and mast cells, which is suggested to involve T-cell
activation and release of T-cell mediators (24). In a murine model for allergic
chapter 7
95
asthma, a shift from Th1 to Th2 type T-cells was prevented by lowering the
amount of available NGF by the use of antibodies directed against NGF (3).
Apart from T-lymphocytes, B-cells synthesize NGF as well. B-cells increase NGF
expression upon stimulation with lipopolysaccharide (LPS) and substance P (10,
37). NGF affects B cells presumably via trkA that is phosphorylated upon
stimulation with NGF (41). No p75 mRNA has been detected in B cells (42). NGF
induces growth and differentiation of B cells and induces antibody synthesis and
secretion from B cells (43).
This indicates that NGF could play a role in the induction of Th2 lymphocytes as
well as differentiation of B lymphocytes; both phenomena important in the
induction of allergic asthma (fig. 1).
2.3. Eosinophils
Eosinophils produce NGF as well (11). As an eosinophil influx into the airways is
reported often in patients with allergic asthma (e.g. 44, 45) and in animal models
for allergic asthma (e.g. 46 and chapter 5), eosinophils can therefore be a potential
source of NGF in allergic asthma.
Furthermore, NGF induces differentiation of eosinophils (24). NGF can act on
human peripheral blood eosinophils to preferentially release inflammatory
mediators (4, 11, 47). NGF enhances survival and cytotoxic activity of human
eosinophils and acts as a chemoattractant (47; fig. 1). This could imply that
antibodies directed against NGF or tyrosine kinase inhibitors for trkA would
reduce eosinophilic infiltration in bronchoalveolar lavage fluid in our model for
allergic asthma. However, we did not find any change in eosinophil numbers after
inhibition of NGF or blocking the phosphorylation of trkA (chapter 5). Most likely,
other chemoattractants for eosinophils overruled the lack of chemoattraction
induced by NGF. It would be interesting to reveal whether eosinophils release less
inflammatory mediators when NGF function is blocked.
2.4. Macrophages
Macrophages are a source of NGF (48) and NGF acts as an autocrine factor. NGF
acts on macrophages presumably via activation of trkA, and enhances release of
IL-1β (49) and induces an increase of Fcγ-receptors (50). It is suggested that
differentiation of monocytes into macrophages is dependent upon trk expression
(51). This implies that neurotrophins are involved in the differentiation of
monocytes into macrophages. Furthermore, NGF is essential for the survival of
macrophages, which are infected with HIV (48). In addition, macrophages regulate
synthesis of NGF in Schwann cells and fibroblast-like cells via IL-1β (52). Taken
together, NGF induces macrophage differentiation, survival and IL-1β release, and
macrophages themselves increase release of NGF by other cell types via IL-1β.
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This implies that macrophages are involved in a worsening of NGF-mediated
pathological effects at several levels (fig. 1).
3. NGF and sensory nerves
In chapter 2 we studied whether increases in NGF could be responsible for changes
in airway function. We showed that application of NGF could induce airway
hyperresponsiveness in vivo. Furthermore, we demonstrated that the induction of
airway hyperresponsiveness was mediated by sensory nerve endings (chapters 2
and 3). The tachykinin substance P, presumably released from the sensory nerves,
is a key player in this respect (chapters 2, 3 and 5; fig. 1).
3.1. Sensory nerve endings
In tracheal rings NGF was able to induce tracheal hyperresponsiveness, which was
mediated by neurokinin-1 receptors (chapter 3). Presumably, NGF did not change
substance P synthesis, as in the tracheal rings sensory nerve endings lacked contact
with their cell bodies. Furthermore, the effects of NGF were established within 1
hr, which makes protein synthesis unlikely (chapters 2 and 3). A very recent study
by Zhou and colleagues showed an increase in substance P release 24 and 48 hrs
after application of 5 ng/ml NGF in tracheal explants (53). In the preparation of
Zhou and colleagues, an increase in substance P formation can also be excluded as
sensory nerve endings lacked contact with their cell bodies (53). We hypothesize
that substance P release is not significantly increased 30 min after addition of NGF
in tracheal explants, as we did not measure a change in basal contraction, but
instead that substance P release is increased upon stimulation with histamine.
NGF can change the properties of sensory nerve endings, without affecting protein
synthesis, in various ways. Indeed, NGF can induce a fast accumulation of second
messengers (54), protein kinase C translocation to the membrane (55) or
phosphorylation of key transduction-related proteins or ion channels (54, 56, 57).
Further evidence for a role of sensory nerve endings in induction of NGF-induced
tracheal hyperresponsiveness is provided by the use of a cannabinoid-1 (CB1)
receptor agonist, which inhibits excitatory processes at the nerve terminal (58). The
CB1 receptor agonist blocked NGF-induced tracheal hyperresponsiveness (chapter
3).
The NGF-induced neuronal changes could be direct, as described above, or
indirect, via the release of sensitizing mediators from trkA expressing
inflammatory cells, e.g. mast cells and monocytes (7, 24, 56, 57, 59). Mediators
released from mast cells, such as histamine and arachidonic acid metabolites have
been suggested to affect neuronal function (60, 61).
Antibodies directed against NGF inhibited the acute bronchoconstriction after
allergen challenge in guinea pigs (chapter 4). Sanico and colleagues, who reported
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a short-term increase in nasal lavage fluid of NGF after allergen provocation,
suggest that this increase in NGF could underlie exaggerated nasal reflexes (62-
67). We demonstrated that NGF can induce neuronal changes, presumably via
substance P. Other studies show that substance P and other tachykinins are
involved in acute allergic responses in the airways. For instance, a role for
substance P in the early allergic response was demonstrated in antigen-induced
microvascular leakage (68). This suggests that NGF could underlie acute changes
of sensory nerve endings by allergic responses (fig. 1). In conclusion, we cannot
exclude that a change in neurokinin-1 receptor functioning underlies the short-term
effects by NGF.
3.2. Substance P synthesis
We discussed effects of NGF in relationship to substance P, which do not involve
increased synthesis of substance P. Besides these effects of NGF on the sensory
nerve ending, NGF-mediated changes seem to involve upregulation of substance P
in the ganglia as well (fig. 1). Hunter and colleagues showed that NGF induced an
increase in substance P positive neurons in the nodose ganglia, 24 hrs after
application of NGF in the tracheal wall (22).
Besides studies that estimated the effect of exogenously applied NGF, there are a
number of studies revealing a role for NGF in inflammatory models. In models for
allergic asthma there is an increase in substance P in the airways and in the number
of substance P positive neurons (16, 69). We showed a prevention of this increase
in substance P by inhibition of the tyrosine kinases of trkA in a guinea pig model
for allergic asthma (chapter 5).
Similarities between allergic asthma and inflammatory pain are abundant. NGF has
been suggested to play an important role in the induction of inflammatory pain (70-
72). Furthermore, in models for pain, NGF was associated with an increase in
substance P (56). In models of inflammatory pain trkA immunoreactivity is
increased (73), pointing to a role for trkA as well.
Interestingly, the development of airway hyperresponsiveness in our allergic
asthma model coincided with an increase in NGF levels and in substance P in
bronchoalveolar lavage fluid 24 hrs after allergen challenge (chapter 5). We
hypothesize that allergen provocation induces NGF release and that NGF in its turn
activates trkA. Subsequently, substance P synthesis is upregulated, resulting in an
increase in substance P in the airways leading to enhanced responsiveness to
bronchoconstrictive agents (fig.1).
3.3. Cholinergic impact
Tachykinin containing nerves innervate cholinergic ganglia in the airways (74, 75).
Baseline airway cholinergic nerve activity is necessarily dependent upon afferent
nerve activity arising from the intrapulmonary airways and lungs, presumably via
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sensory nerves (76, 77). Excessive activity of cholinergic nerves may be important
in asthma (78, 79).
Vagal activation can induce bronchospasm, which can be reversed by tachykinin
receptor antagonists (80). Furthermore, in the airways contraction is partly
cholinergic when evoked by substance P (81-84) or neurokinin A (85).
Additionally, tachykinins can augment cholinergic transmission (85, 86).
Moreover, NGF could increase histamine-induced smooth muscle contraction and
this could be blocked by a neurokinin-1 receptor antagonists (chapter 2 and 3). We
can not exclude involvement of cholinergic neurotransmission in this respect.
Parasympathetic ganglia are located in the trachea, thus in a tracheal preparation
NGF-induced tracheal hyperreactivity could involve (augmented) release of
acetylcholine (chapter 3; fig. 2). Further experiments using a cholinergic blocker














Figure 2. Hypothetical scheme of action of NGF via cholinergic ganglion, which is
positioned in the trachea. NGF could change the substance P (SP) release from the
sensory nerve ending, innervating a cholinergic ganglion, or could enhance
neurokinin receptor (NK-R) function on a cholinergic ganglion. This could induce
an enhanced acetylcholine release (ACh), which could induce an enhanced smooth
muscle contraction, via cholinergic receptor (Ch-R) activation.
3.4. Vanilloid receptor
The receptor involved in reaction to the exogenous compound capsaicin, earlier
known as the capsaicin receptor, has now been idetified as vanilloid receptor 1
(VR1). Endogenous ligands of this receptor were unknown till recently
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anandamide, an endogenous cannabinoid, was shown to act as a full agonist on
VR1 (87). Very recently, it was shown that products of lipoxygenases directly
activate capsaicin receptors (88). These products are, in order of increasing
potency: 12-hydroperoxyeicosatetraenoic acid (12-HPETE), 15-HPETE, 5-
hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4. This indicates that, in
case of an inflammatory situation, in which different lipoxygenase products are
upregulated, VR1 receptors could be activated. As previously shown, mediators
like leukotriene B4 and other leukotrienes play a role in allergic asthma (89, 90)
and pathological effects can be reversed by blocking leukotriene synthesis or

















Figure 3. Schematic representation of possible involvement of the vanilloid receptor-1
(VR1) in induction of tracheal hyperresponsiveness. Either inflammation or possibly NGF
could induce changes in mast cells or sensory nerve endings. Lipoxygenase (LOX)
products released from mast cells, or from other cells releasing lipoxygenase products,
could activate the VR1 on the sensory neuron, thereby inducing release of tachykinins, for
instance substance P (SP), which could in turn activate the neurokinin-1 receptor (NK1-R),
and subsequently induce airway hyperresponsiveness. Alternatively, VR1 receptors present
on the mast cell could be activated as well, inducing an enhanced release of inflammatory
mediators.
NGF induces a rapid enhancement of the response to capsaicin (94). This implies
that NGF enhances the effects of the lipoxygenase products on the VR1 as well.
NGF: possible mechanisms of interaction in allergic airway pathologies
100
This mechanism could account for an exacerbation of the pathological effects in
allergic inflammation.
With respect to the data presented in the previous chapters, we postulate a novel
mechanism. In the guinea pig model for allergic asthma (chapter 4 and 5),
inflammatory mediators and presumably lipoxygenase products, were released (89-
93). Such lipoxygenase products can activate VR1 while NGF could have enhanced
VR1 activation (fig. 3). This cascade could have induced an increase in the release
of substance P and thus enhanced neurogenic inflammation, leading to, for
instance, airway hyperresponsiveness. It would be interesting to have a closer look
at activation of the VR1.
Whether or not  this sequence of events is also operational in vivo in an
inflammatory situation remains open to investigation. In favor of this view are two
recent studies in which VR1 knockout mice do not show inflammatory thermal
hyperalgesia (95, 96). This implies that in a normal inflammatory situation VR1 is
activated and induces inflammatory pain. Caterina and colleagues speculated on
anandamide, a cannabinoid, as an endogenous ligand for VR1 (87, 95, 97).
Interestingly, tissue injury increases the levels of endogenous cannabinoids (98).
However, there are no other studies, to our knowledge, that have measured
anandamide in inflammatory situations. Therefore, at this moment we can merely
suggest that lipoxygenase products could have been involved in inflammatory pain.
We speculated on a role for VR1 in inflammatory models. The direct effects of
NGF, mediated by substance P on airway function (chapter 2 and 3), could have
been mediated by VR1 as well. Activation of VR1 induces release of sensory
peptides including substance P. In an allergic situation, increases in lipoxygenase
products have been reported, though not in naïve animals. As NGF stimulates the
release of mediators from a variety of inflammatory cells, maybe NGF induces
release of lipoxygenase products (9, 11, 24, 30, 43, 49, 99, 100). Therefore,
activation of the VR1 could play a role in induction of hyperresponsiveness by
NGF in naïve animals when lipoxygenase products are released after NGF
application.
Could activation of VR1 receptors be responsible for the increase of substance P in
the airways in a model for allergic asthma? Normally, tachykinergic innervation in
guinea pig airways is derived almost exclusively from small unmyelinated C-
fibers. In allergic models, an increase in substance P producing large diameter,
myelinated neurons is found in the nodose ganglia, being Aδ-fibers (16, 69). As
mentioned before, this increase in substance P in nodose ganglia can be mimicked
by application of NGF (22). Unlike C-fibers, Aδ-fibers are insensitive to
bradykinin and capsaicin (16, 22). This indicates that these neurons do not express
VR1 and thus stimulation of VR1 can not responsible for the increased content of
substance P derived from Aδ-fibers in the airways. However VR1 can be
responsible for increases in tachykinins from C-fibers (chapter 5; 16, 69). Another
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interesting experiment would be to have a closer look at the capsaicin receptors
themselves: either at the number or the function of the receptors.
VR1 receptors could be involved in other pathologic changes in airway
inflammation, besides the changes in tachykinin release. Indeed, mast cells express
VR1 and respond directly to capsaicin (101). Using capsaicin provides further
indirect evidence. Capsaicin has tachykinin-independent effects on smooth muscle
in bronchi (102) and capsaicin induces release of inflammatory cytokines from
bronchial epithelium (103). This all points to the possibility that VR1 mediates
effects which do not involve tachykinin release but could be involved in the
induction of airway hyperresponsiveness.
Some previously published studies should be carefully reevaluated and
assumptions made could be changed in view with the posibility of activation of the
VR1. For instance, 15-HPETE has been shown to induce airway
hyperresponsiveness by affecting nerve endings (104). We could postulate that 15-
HPETE activated VR1, thereby inducing release of sensory neuropeptides.
Furthermore, inhibition of a 5-lipoxygenase diminishes electrically evoked
tachykinergic mediated contractions in airway tissue (105). Other inflammatory
mediators, such as bradykinin, 5-hydroxytryptamine and prostaglandin E2 do
activate the capsaicin receptor, as the capsaicin antagonist capsazepine could
completely block currents induced by these mediators (106). Caterina and
colleagues suggest that this effect of bradykinin is mediated via the release of
lipoxygenase products (95). Very many studies show effects of bradykinin via
release of sensory neuropeptides (e.g. 107, 108). This implicates that bradykinin
acts directly or indirectly on VR1. Studies in our department provide evidence that
the lipid mediator 13-hydroxyoctadecadienoic acid (13-HODE) induces airway
hyperresponsiveness via sensory neuropeptides (109). As 13-HODE is another
product of 15-lipoxygenase, it could be that 13-HODE acts via VR1 as well.
4. NGF and hyperresponsiveness
4.1. NGF induces hyperresponsiveness
A single injection of NGF in guinea pigs induced airway hyperresponsiveness
(chapter 2). This effect was transient as at 24 hrs after administration of NGF no
airway hyperresponsiveness could be measured anymore (chapter 2). In patients
suffering from allergic asthma, an airway hyperresponsiveness is a phenomenon
which can be found at any moment (113). How can we correlate this to our data?
We showed recently, that intravenous administration of NGF for three days every
day could induce airway hyperresponsiveness 24 hrs after the last of the three
injections in guinea pigs (fig. 4). Furthermore, as patients are normally exposed to
allergens continuously and NGF is upregulated after allergen challenge (1, 13, 114)
they are likely to suffer from sustained high levels of NGF. Therefore, our results
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with repeated application of NGF provides more evidence for the importance of
NGF in the development of airway hyperresponsiveness in allergic asthma.
























Figure 4. Intravenous application of NGF (80 ng/kg) to guinea pigs for 3 days every 24 hrs
results in an airway hyperresponsiveness to histamine 24 hrs after the last intravenous
injection of NGF (* P<0.0001 two-way ANOVA). See chapter 2 for materials and methods.
Our observation that anti-NGF does not attenuate the airway hyperresponsiveness
in our guinea pig model is in contrast with the findings of Braun and colleagues,
who did demonstrate a reduction in airway hyperresponsiveness by treatment with
antibodies directed against NGF (3). The difference in effects could be due to a
species difference, as our data are obtained from guinea pigs whereas Braun and
colleagues used mice. Furthermore, it is hard to compare both studies since they
involve different parameters: we measured changes in peptide expression in nerves
in guinea pigs, whereas Braun and colleagues measured a shift from Th1 to Th2
type lymphocytes in mice (3). Recently, it has been shown that in models for pain
as well that administration of NGF antibodies was insufficient to inhibit the
induction of pain (110). Though in other studies neutralization of NGF was
successfully inhibiting pain (111, 112).
4.2. Substance P
Blocking tyrosine kinases of the trkA completely prevented the induction of airway
hyperresponsiveness and of substance P increases; this suggests a causal
relationship between substance P and the induction of airway hyperresponsiveness
(fig. 1). Moreover, a role for substance P in the induction of airway
hyperresponsiveness has been reported in animal models (19-21) as well as for
other tachykinins (109, 115; recently reviewed in 116). Also, tachykinin levels are
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elevated in asthmatics (117) and protective effects of neurokinin receptor
antagonists have been reported (118, 119). Here also, a similarity between the
induction of inflammatory pain and allergic asthma seems to exist, as increases in
substance P and NGF have been associated with pain (112, 120).
4.3. Neurotrophin 3
The partial inhibitory effect of anti-NGF on increases of substance P and the lack
of effect of anti-NGF on ovalbumin-induced airway hyperresponsiveness could be
explained by the action of neurotrophin 3 (NT-3). NGF is the neurotrophic factor
with the highest binding affinity for trkA (121). NT-3 binds preferentially to its
high-affinity receptor trkB, but can also bind and activate trkA, though with a
lower affinity than NGF (122). As NT-3 is elevated in bronchoalveolar lavage fluid
after allergen challenge in patients with allergic asthma (1) and NT-3 has been
shown to be able to induce substance P release (123), we suggested that NT-3
could still activate trkA and thereby causing airway hyperresponsiveness (chapter
5).
4.4. TrkA and p75
Apart from NT-3 involvement, an alternative explanation for the lack of effect of
treatment with antibodies directed against NGF in our guinea pig model for allergic
asthma could imply an activation of p75. This receptor can also bind brain derived
neurotrophic factor (BDNF), NT-3 and NT-4. The two receptors for NGF, p75 and
trkA, have been shown to change each other's functioning negatively or positively.
It could be that, in case of administration of antibodies against NGF, activation of
p75 by BDNF or NT-3 could have a positive effect on trkA function, and therefore
enhance NT-3 action on trkA. This could occur as NGF, NT-3 and BDNF are
increased in bronchoalveolar lavage fluids 18 hr after allergen challenge (1). These
neurotrophic factors bind with similar binding affinities, but p75 can distinguish
between them and therefore exert different effects (121).
The p75 does not use tyrosine kinases for its signal transduction, therefore its
functioning is not affected when using tyrosine kinase inhibitors. The p75 binds
each of the neurotrophins with low nanomolar affinity (124). Receptor complexes
and functional interactions between p75 and trkA have been reported and the
balance between effects exerted by p75 and trkA is very complex (121). The final
effect exerted is dependent upon the type of cells and the microenvironment (124).
So far, no studies addressed this issue in airway tissue. Further experiments are
needed to reveal whether or not interactions between the two NGF receptors are
important for the development of airway pathologies.
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4.5. Immune cells as a source for substance P
So far we merely speculated about the induction and release of substance P from
sensory nerves. However, substance P is not only derived from nerves, but also
from various other immune cells: eosinophils, monocytes, macrophages,
lymphocytes and dendritic cells (125-127). In patients with asthma, the
concentrations of substance P was significantly related to the eosinophil cell count
in induced sputum (128, 129). The substance P could be directly released by the
eosinophils, or mediators released from the eosinophils induced substance P
release from sensory neurons (130). Furthermore, substance P by itself affects
immune cell function, for instance recruitment of eosinophils and neutrophils
(131), mast cell activation and threshold lowering (132-134) and lymphocyte
proliferation (127). In this way, immune cell-derived substance P could further
worsen the pathologic effects in allergic asthma (79). These alternative pathways
of substance P release and effects on immune cell functioning could be involved in
the development of allergic asthma and airway hyperresponsiveness.
5. NGF in other inflammatory diseases
NGF is elevated and has a role in other inflammatory diseases besides allergic
asthma. For instance, NGF and trkA are upregulated in the gut in patients suffering
from inflammatory bowel disease (135). Furthermore, NGF levels are elevated in a
number of autoimmune states (136, 137) and in allergic diseases such as
rhinoconjunctivis, urticaria-angioedema, vernal keratoconjunctivitis and allergic
rhinitis (2, 4, 13, 138, 139).
NGF plays a role in inflammatory pain, as mentioned previously (70, 112, 140).
We showed a reducing effect of NGF blockade on airway pathology in a model for
allergic asthma (chapter 4 and 5). Likewise, a tyrosine kinase inhibitor specific for
trkA has beneficial effects in a model for experimental autoimmune
encephalomyelitis, by its ability to suppress macrophage activation (141). Also,
blocking NGF has a beneficial effect in inflammatory pain (111, 142). Taken
together, this indicates that blocking of NGF is a potential target in inflammatory
diseases.
On the other hand, a lack of NGF induces neural pathology (143, 144). In type 1
diabetes a downregulation of available NGF is measured. Diabetes is associated
with severe neuro-pathologies (145, 146). Depletion in substance P (147), which is
another phenomenon of diabetes, can be reversed by application of NGF in
streptozotocin-induced diabetes in rats (148). Very interesting is a recent
observation that shows that children with type-1 diabetes and their unaffected
siblings have fewer symptoms of asthma (149). When co-existence does occur, the
cases are generally mild, and effective treatment of one disease frequently
exacerbates the other (150). Obviously, asthma has a typical Th2 type pathology,
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and type 1 diabetes is a typical Th1-mediated disease. However, non-co-existence
of asthma and diabetes could be caused by a lack or increase in NGF, especially
since NGF has profound effects on T-cells as well (3, 9, 24, 36-39). This shows a
critical balance for NGF, as too little is associated with neuropathologies and
maybe a Th1 shift, whereas too much NGF seems to enhance inflammatory
pathology and Th2 cell development.
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Nerve growth factor (NGF) is al jarenlang bekend als groeifactor voor zenuwen.
Het zorgt bijvoorbeeld voor de uitgroei van zenuwen tijdens de ontwikkeling van
een embryo. Recentelijk is gebleken dat dit soort groeifactoren ook een rol speelt
in ontsteking. Tijdens een ontsteking is de hoeveelheid NGF ter plekke verhoogd.
Allergisch astma wordt o.a. door ontsteking in de luchtwegen gekenmerkt. In dit
proefschrift is onderzocht in hoeverre NGF een rol speelt in allergisch astma.
Gezonde mensen reageren niet of nauwelijks op koude lucht of andere prikkels,
maar patiënten met astma reageren hierop met een luchtwegvernauwing. Deze
overgevoeligheid van de luchtwegen kan in de cavia worden nagebootst door
simpelweg een kleine hoeveelheid NGF toe te dienen. Dit is beschreven in
hoofdstuk 2.
Er zijn zenuwen die weliswaar signalen afgeven aan de luchtwegen, maar bovenal
signalen doorgeven van de luchtwegen naar de hersenen. Dit zijn de zogenaamde
sensorische zenuwen. Een bepaalde soort sensorische zenuwen brengt een aantal
zeer specifieke peptiden tot expressie. Dit zijn de tachykininen, waaronder
substance P en neurokinine A. De tachykininen kunnen luchtwegovergevoeligheid
veroorzaken. NGF lijkt zijn effecten te bewerkstelligen door deze zenuwen
overgevoelig te maken. Dit betekent dat de zenuwen op een prikkel sneller
reageren of meer substance P afgeven. Indien vlak vóór de toediening van NGF de
receptor voor substance P wordt geblokkeerd, dan kan de overgevoeligheid van de
luchtwegen voorkomen worden (hoofdstuk 2). Hoofdstuk 3 laat zien dat NGF
overgevoeligheid van de luchtwegen veroorzaakt via de zenuwuiteinden, maar
zonder dat er meer substance P wordt geproduceerd.
Hoofdstuk 3 bevat nog een aanwijzing dat zenuwuiteinden betrokken zijn bij de
inductie van luchtwegovergevoeligheid door NGF. Een cannabinoid blijkt in staat
de effecten van NGF in zowel het trachea-preparaat als in het hele dier te
blokkeren. De gebruikte cannabinoid stimuleert specifiek de cannabinoid receptor
op sensorische zenuwen, en zorgt ervoor dat de zenuwen minder signalen
doorgeven.
Ook is in een diermodel voor allergisch astma gekeken naar de rol van NGF. Een
cavia kan overgevoelig worden gemaakt voor ovalbumine, een eiwit uit het kippen-
ei. Op het moment dat de cavia ovalbumine inademt, reageert het dier met een
allergische aanval in de luchtwegen. Als vlak voor de ovalbumine antistoffen tegen
NGF worden toegediend, die er dus voor zorgen dat de hoeveelheid NGF sterk
verlaagd wordt, is de acute allergische luchtwegvernauwing sterk verminderd
(hoofdstuk 4).
Verder treedt er in dit diermodel een dag na de inademing van ovalbumine een
overgevoeligheid van de luchtwegen op. Dit gaat gepaard met een verhoging van
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substance P in de zenuwen. In hoofdstuk 5 is aangetoond dat tegelijkertijd de
hoeveelheid NGF in de longen toeneemt. De dieren zijn behandeld met tyrosine
kinase remmers specifiek voor de receptor met een hoge affiniteit voor NGF: de
tyrosine kinase receptor A (trkA). Deze remmers zorgen ervoor dat NGF zijn
signalen via de trkA receptor niet meer kan doorgeven. Als de dieren met deze
tyrosine kinase remmers behandeld worden, is de overgevoeligheid van de
luchtwegen verdwenen en is ook de hoeveelheid substance P niet meer verhoogd in
het diermodel voor allergisch astma (hoofdstuk 5).
Opvallend is dat antistoffen tegen NGF de overgevoeligheid van de luchtwegen
niet kunnen voorkomen, terwijl blokkade van trkA signalering wel effectief is in
dit diermodel voor astma. De acute-astma aanval daarentegen, zoals beschreven in
hoofstuk 4, kan wel door antistoffen tegen NGF en niet door remming van de
tyrosine kinases van de trkA receptor worden verminderd. Onze hypothese is dat er
nog een andere neurotrofe factor betrokken is bij allergisch astma die ook via de
trkA receptor werkt.
NGF kan uit verschillende cellen worden vrijgezet. Eén van die cellen is de
mestcel. Al vaker is in de literatuur directe communicatie tussen mestcellen en
sensorische zenuwen gesuggereerd. Deze twee typen cellen zijn samen gekweekt
en er is onderzocht in hoeverre de cellen elkaars functie beïnvloeden (hoofdstuk 6).
In onze experimenten hechten de cellen specifiek aan elkaar. Verder beïnvloeden
deze cellen elkaar wel, maar slechts in geringe mate. Meer studies zijn nodig om
deze interacties nader te bestuderen. Op dit moment kunnen we nog geen uitspraak
doen of de mestcellen betrokken zijn bij de vrijzetting of effecten van NGF in de
luchtwegen.
Concluderend kan gesteld worden dat de effecten van NGF in de luchtwegen
bewerkstelligd worden door veranderingen in de sensorische zenuwen. In dit
proefschrift is aangetoond dat NGF een rol in allergisch astma speelt. Dit kan de
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